🏷

Classifications

Harrison's Part

Channelopathy

🔗

Mappings

MONDO

MONDO:0014921 developmental and epileptic encephalopathy, 43

MONDO:0014921 (developmental and epileptic encephalopathy, 43; OMIM:617113) is the MONDO class explicitly gene-associated with GABRB3 (RO:0004003 to hgnc:4083) and is the exact scope of this entry: the encephalopathic end of the GABRB3 allelic spectrum. The milder GABRB3 phenotypes are deliberately excluded from this entry's scope and are recorded as differentials.

👪

Inheritance

1

Autosomal dominant (almost always de novo) HP:0000006

DEE43 is inherited in an autosomal dominant manner, but affected individuals almost always carry a de novo heterozygous variant rather than an inherited one. In a Chinese multicenter cohort, 25 of 26 GABRB3 variants were de novo. Rare inherited transmission occurs, including from a clinically unaffected parent; a reported nonsense variant (p.Trp2Ter) was maternally inherited. Because most variants are de novo, recurrence-risk counselling should consider the possibility of undetected parental gonadal mosaicism.

Autosomal dominant inheritance

Show evidence (2 references)

PMID:34698933 SUPPORT Human Clinical

"Thirteen GABRB3 variants were novel, and 25 were de novo."

Quantifies the de novo fraction (25 of 26 variants) in a multicenter GABRB3 epilepsy cohort, supporting a dominant, predominantly de novo mechanism.

PMID:29390378 SUPPORT Human Clinical

"Sanger sequencing showed the mutation was present in her mother and absent in her father, indicating a maternal origin."

Documents the exception to the de novo rule — an inherited (maternally transmitted) GABRB3 nonsense variant in a child with early-onset epileptic encephalopathy. Marked PARTIAL because a single case report establishes that inherited transmission occurs without quantifying how often.

◈

Mechanistic Hypotheses

1

Gain-of-function severity arises from excess tonic (extrasynaptic) GABAergic current during development

gof_tonic_current_excess EMERGING

Evidence balance 1 support

Under this model, the reason gain-of-function GABRB3 variants cause the more severe encephalopathy is that increased GABA potency preferentially amplifies tonic currents carried by extrasynaptic receptors responding to low ambient GABA. Excess tonic inhibition during the period when GABAergic signalling patterns developing circuits is proposed to be as damaging as too little. The strongest support is pharmacological and indirect: vigabatrin, which raises tonic GABA current, produces hypotonia, sedation, and respiratory suppression specifically in gain-of-function patients, whereas benzodiazepines, which act mainly on phasic synaptic currents, do not. It is recorded as EMERGING rather than canonical because no study has yet measured the proposed tonic-current excess in patient neurons or shown that normalizing it reverses the phenotype.

Pathograph links

Gain-of-Function Increase in GABA Sensitivity -> Disrupted Excitation-Inhibition Balance in Developing Networks INDIRECT KNOWN INTERMEDIATES Excess tonic GABAergic conductance in immature cortical and thalamocortical circuits disturbs, rather than restores, network balance.

Show evidence (1 reference)

PMID:33585817 SUPPORT In Vitro

"We therefore propose that the hypersensitivity reaction to vigabatrin is a result of GABRB3 variants that exacerbate GABAergic tonic currents and caution is required when prescribing vigabatrin."

States the tonic-current-excess model directly, as the proposed explanation for the gain-of-function vigabatrin hypersensitivity.

?

Discussions and Knowledge Gaps

2

Why do gain-of-function GABRB3 variants — which increase the potency of an inhibitory neurotransmitter receptor — produce an earlier-onset and more severe epileptic encephalopathy than loss-of-function variants?

CONTROVERSY OPEN controversy_gabrb3_gof_paradox

Attached to

pathophysiology#Gain-of-Function Increase in GABA Sensitivity pathophysiology#Disrupted Excitation-Inhibition Balance in Developing Networks

The excitation-inhibition framework predicts that reduced GABAergic inhibition causes seizures, and GABA-A receptor epilepsy variants were presumed to act that way. GABRB3 breaks the prediction: the class of variants that increases GABAergic activity has the worse outcome. Candidate explanations include preferential amplification of tonic extrasynaptic current, depolarizing GABA responses in immature neurons with high intracellular chloride, and disruption of the developmental patterning role of GABAergic signalling — but these have not been discriminated experimentally, and the answer determines whether GABA-enhancing drugs help or harm a given patient.

Show evidence (1 reference)

PMID:35383156 SUPPORT Human Clinical

"Overall, patients with GABRB3 variants that increase GABAergic activity have more severe developmental and epileptic encephalopathies. This paradoxical finding challenges our current understanding of the GABAergic system in epilepsy and how patients should be treated."

States the paradox and its unresolved status in the authors' own words.

Do the available Gabrb3 mouse models represent the human gain-of-function arm of DEE43, or only its loss-of-function arm — and can drug-response findings from them (notably cannabidiol) be generalized across the two functional classes?

HUMAN MODEL MISMATCH OPEN mismatch_gabrb3_mouse_models_lof_only

Attached to

pathophysiology#Gain-of-Function Increase in GABA Sensitivity

Every in vivo Gabrb3 model in current use sits on one side of the human disease. The constitutive knockout removes the subunit entirely, which is a loss-of-function extreme and additionally produces an Angelman-like phenotype rather than DEE43. The two knock-in lines (D120N, N328D) each model a single Lennox-Gastaut-associated human variant. No published model reproduces the reduced-desensitization gain-of-function subgroup that carries the earliest onset, movement disorder, and early-mortality risk in patients. This matters concretely: cannabidiol efficacy has been shown in the D120N line and is being read as a rationale for human use, but the functional class of D120N cannot be assumed to represent the gain-of-function patients in whom GABA-directed drugs behave oppositely.

Show evidence (2 references)

PMID:9763493 SUPPORT Model Organism

"The loss of the single gene, gabrb3, in these mice is sufficient to cause phenotypic traits that have marked similarities to the clinical features of AS, indicating that impaired expression of the GABRB3 gene in humans probably contributes to the overall phenotype of Angelman syndrome."

Shows the knockout is framed and validated as an Angelman syndrome model, not as a model of the human GABRB3 DEE gain-of-function spectrum.

PMID:42274296 SUPPORT Model Organism

"Gabrb3+/D120N mice display robust atypical absence seizures and neonatal spasms that respond to antiseizure agents, supporting the predictive validity of this model as a preclinical platform for LGS drug discovery."

States the predictive-validity claim that this mismatch discussion asks to be tested across functional classes rather than assumed.

⚙

Pathophysiology

9

GABRB3 Variant and Beta-3 Subunit Dysfunction

A heterozygous, usually de novo, GABRB3 variant (predominantly missense, less often nonsense or truncating) alters the beta-3 subunit of the GABA-A receptor. The beta-3 subunit is highly expressed in the developing brain and is a component of the principal native synaptic (alpha1-beta3-gamma2) and extrasynaptic (alpha5-beta3-gamma2) receptor assemblies, so a single heterozygous variant perturbs a large fraction of brain GABA-A receptors.

GABAergic neuron CL:0000617

Genetic context GABRB3 hgnc:4083 variant_origin: DE_NOVO zygosity: HETEROZYGOUS

GABA-A receptor activity GO:0004890 ⚠ ABNORMAL

GABA-A receptor complex GO:1902711

brain UBERON:0000955

Downstream

Gain-of-Function Increase in GABA Sensitivity One class of missense variants increases the potency of GABA at the mutant receptor.

Loss-of-Function Reduction in GABA-A Receptor Function The other class reduces receptor function, by lowering GABA-evoked current or by impairing subunit assembly and delivery.

Show evidence (2 references)

PMID:26645412 SUPPORT Human Clinical

"The gamma-aminobutyric acid type A receptor β3 gene (GABRB3) encodes the β3-subunit of the gamma-aminobutyric acid type A (GABAA ) receptor, which mediates inhibitory signalling within the central nervous system."

Establishes the gene product and its role as a subunit of the receptor mediating inhibitory signalling, the molecular starting point of this disease chain.

PMID:31435640 SUPPORT Other

"GABRB3 is highly expressed early in the developing brain, and its encoded β3 subunit is critical for GABAA receptor assembly and trafficking as well as stem cell differentiation in embryonic brain."

Supports the developmental expression and assembly/trafficking role of the beta-3 subunit that makes a heterozygous variant consequential. Evidence source is OTHER because this sentence is background framing citing prior work rather than a result of this study's own experiments.

Gain-of-Function Increase in GABA Sensitivity

Gain-of-function variants raise the potency of GABA at the receptor (a leftward shift in the GABA concentration-response relationship) without necessarily changing maximal open probability or absolute current. Because tonic, extrasynaptic inhibition is driven by low ambient GABA concentrations, a potency increase disproportionately amplifies tonic chloride flux. Counterintuitively for a receptor whose job is inhibition, this class carries the more severe clinical phenotype: younger seizure onset, higher risk of severe intellectual disability, focal seizures at onset, hypotonia, and lower likelihood of seizure freedom.

Gain-of-function severity arises from excess tonic (extrasynaptic) GABAergic current during development

chloride transmembrane transport GO:1902476 ↑ INCREASED

GABA-A receptor activity GO:0004890 ⇑ GAIN OF FUNCTION

Downstream

Altered Receptor Desensitization Within the gain-of-function class, desensitization kinetics further tune how much excess chloride flux persists at equilibrium.

Disrupted Excitation-Inhibition Balance in Developing Networks Excess tonic GABAergic conductance in immature cortical and thalamocortical circuits disturbs, rather than restores, network balance.

Show evidence (2 references)

PMID:35383156 SUPPORT Human Clinical

"The gain-of-function cohort (n = 27 patients) presented with a younger age of seizure onset, higher risk of severe intellectual disability, focal seizures at onset, hypotonia, and lower likelihood of seizure freedom in response to treatment."

Defines the gain-of-function class and its distinct, more severe clinical profile in a 74-patient cohort.

PMID:33585817 SUPPORT In Vitro

"Results showed an atypical gain-of-function molecular phenotype in the GABRB3 p.Glu77Lys and p.Thr287Ile variants characterized by increased potency of γ-aminobutyric acid A without change to the estimated maximum open channel probability, deactivation kinetics or absolute currents."

Provides the electrophysiological definition of the gain-of-function phenotype as increased GABA potency rather than increased maximal current.

Altered Receptor Desensitization

Desensitization — the decline of current during sustained agonist exposure — is a second, independent axis of gain-of-function severity. Variants that reduce desensitization at equilibrium sustain the excess conductance and worsen gain-of-function traits; these cluster in the pore-forming transmembrane region and are associated with the most severe outcomes (median first-seizure onset 0.5 months, movement disorder, migrating focal seizures, and risk of early mortality). Variants that instead accelerate current decay limit the gain-of-function effect, cluster in the activation coupling loops, and are associated with later onset and milder phenotypes.

GABA-A receptor activity GO:0004890 ⚠ ABNORMAL

Downstream

Disrupted Excitation-Inhibition Balance in Developing Networks

Show evidence (2 references)

PMID:37647766 SUPPORT In Vitro

"Of the 20 gain-of-function variants assessed, 13 were found to alter receptor desensitization properties. Seven variants reduced desensitization at equilibrium, which acts to worsen gain-of-function traits. Six variants accelerated current decay kinetics, which limits gain-of-function traits."

Establishes desensitization as a distinct modifier of the gain-of-function molecular phenotype, in two opposite directions.

PMID:37647766 SUPPORT Human Clinical

"This included younger age of first seizure onset (median 0.5 months), movement disorders (dystonia and dyskinesia), epilepsy of infancy with migrating focal seizures (EIMFS) and risk of early mortality."

Links reduced desensitization at equilibrium to the most severe clinical subgroup, including movement disorder and early-mortality risk.

Loss-of-Function Reduction in GABA-A Receptor Function

The other functional class reduces GABA-A receptor function, the mechanism originally presumed to account for all GABA-A receptor epilepsies. These patients have a distinct clinical signature: febrile seizures at onset occur exclusively in this group, and treatment response is comparatively better.

inhibitory postsynaptic potential GO:0060080 ↓ DECREASED

GABA-A receptor activity GO:0004890 ⇓ LOSS OF FUNCTION

Downstream

Impaired Receptor Trafficking and Postsynaptic Clustering A recurrent cellular route to loss of function is failure to deliver and retain receptors at inhibitory synapses.

Disrupted Excitation-Inhibition Balance in Developing Networks

Show evidence (2 references)

PMID:35383156 SUPPORT Human Clinical

"Febrile seizures at onset are exclusive to the loss-of-function cohort (n = 47 patients)."

Defines the loss-of-function class as a separable cohort with its own clinical onset signature.

PMID:35383156 SUPPORT Other

"These variants are presumed to cause loss-of-function receptors leading to reduced neuronal GABAergic activity."

States the prior assumption that GABA-A receptor epilepsy variants act by loss of function — the framing this entry's two-class model revises. Evidence source is OTHER because this sentence states the field's background assumption rather than reporting the study's own data.

Impaired Receptor Trafficking and Postsynaptic Clustering

Mutant beta-3 subunits reduce surface and synaptic receptor levels and, more strikingly, act in trans on the wild-type receptor pool: they impair postsynaptic clustering of wild-type gamma-2 subunits and prevent gamma-2 from being incorporated into synaptic GABA-A receptors. Because gamma-2 is what anchors GABA-A receptors at the synapse, this converts a heterozygous subunit defect into a broader loss of synaptic inhibitory receptors. The same reduction in synaptic gamma-2 clustering is seen in Gabrb3 heterozygous knockout mice.

GABAergic neuron CL:0000617

GABA-A receptor localization to the plasma membrane GO:0072659 ↓ DECREASED

GABA-ergic synapse GO:0098982

Downstream

Disrupted Excitation-Inhibition Balance in Developing Networks

Show evidence (3 references)

PMID:31435640 SUPPORT In Vitro

"Interestingly, both mutant β3 subunits impaired postsynaptic clustering of wild-type GABAA receptor γ2 subunits and prevented γ2 subunits from incorporating into GABAA receptors at synapses, although by different cellular mechanisms."

Demonstrates the trans-acting clustering defect by which mutant beta-3 subunits deplete synaptic receptors beyond simple haploinsufficiency.

PMID:31435640 SUPPORT In Vitro

"This suggests that impaired receptor localization to synapses is a common pathophysiological mechanism for GABRB3 mutations, although the extent of impairment may be different among mutant subunits."

Generalizes impaired synaptic localization as a shared cellular mechanism across GABRB3 variants, with variant-dependent severity.

PMID:31435640 SUPPORT Model Organism

"Importantly, wild-type γ2 subunits were reduced and less clustered at inhibitory synapses in Gabrb3+/- knockout mice."

Confirms the synaptic clustering deficit in vivo in a heterozygous Gabrb3 mouse, showing it is not an artifact of heterologous expression.

Disrupted Excitation-Inhibition Balance in Developing Networks

Both functional classes converge here. GABA-A receptor signalling in developing cortical, hippocampal, and thalamocortical circuits is displaced from its normal set point — reduced in loss-of-function variants, excessive and mistimed (particularly in the tonic, extrasynaptic compartment) in gain-of-function variants. Either displacement destabilizes the balance between excitation and inhibition. In the Gabrb3 D120N knock-in mouse this manifests as reduced miniature inhibitory postsynaptic current amplitude in cortical neurons and prolonged spontaneous thalamocortical oscillations.

GABAergic neuron CL:0000617 pyramidal neuron CL:0000598

gamma-aminobutyric acid signaling pathway GO:0007214 ⚠ ABNORMAL synaptic transmission, GABAergic GO:0051932 ⚠ ABNORMAL

brain UBERON:0000955

Downstream

Neuronal Hyperexcitability and Thalamocortical Hypersynchrony

Show evidence (3 references)

PMID:32467926 SUPPORT Model Organism

"However, cortical neurons in thalamocortical slices from knock-in mice had reduced miniature inhibitory post-synaptic current amplitude and prolonged spontaneous thalamocortical oscillations."

Provides direct circuit-level evidence that a disease-causing GABRB3 variant shifts inhibitory synaptic drive and prolongs thalamocortical oscillations.

PMID:32467926 SUPPORT Model Organism

"Thus, the Gabrb3+/D120N knock-in mouse recapitulated human Lennox-Gastaut syndrome seizure types and behavioural abnormalities and was caused by impaired inhibitory GABAergic signalling in the thalamocortical loop."

Attributes the modelled human seizure phenotype specifically to impaired inhibitory GABAergic signalling in the thalamocortical loop.

PMID:9108119 SUPPORT Model Organism

"GABA(A)-R density is approximately halved in brain of beta3-deficient mice, and GABA(A)-R function is severely impaired."

Shows that removing the beta-3 subunit halves brain GABA-A receptor density and severely impairs receptor function, the loss-of-function extreme of this node.

Neuronal Hyperexcitability and Thalamocortical Hypersynchrony

The destabilized network fires excessively and synchronously. In patients this is visible as ictal generalized and interictal multifocal epileptiform abnormalities on EEG; in the D120N knock-in mouse it appears as prolonged spontaneous thalamocortical oscillations underlying atypical absence seizures.

neuron CL:0000540

action potential GO:0001508 ↑ INCREASED

brain UBERON:0000955

Downstream

Seizure Generation and Developmental Encephalopathy

Show evidence (2 references)

PMID:26645412 SUPPORT Human Clinical

"Electroencephalography demonstrated ictal generalized and interictal multifocal epileptiform abnormalities."

Documents the hypersynchronous discharges in a molecularly confirmed GABRB3 patient.

PMID:9763493 SUPPORT Model Organism

"Disrupting the gabrb3 gene in mice produces electroencephalographic abnormalities, seizures, and behavior that parallel those seen in AS."

Shows that beta-3 subunit disruption alone is sufficient to produce electroencephalographic abnormality and seizures in vivo.

Seizure Generation and Developmental Encephalopathy

Hypersynchronous discharges become clinical seizures, typically starting in the first year of life and typically of several types in the same child. Because the same receptor defect that generates seizures also disturbs GABAergic signalling during a period when it is shaping circuit development, the developmental impairment is not simply a consequence of seizure burden — which is what the "developmental and epileptic encephalopathy" designation is intended to capture.

neuron CL:0000540

Downstream

Drug-Resistant Epilepsy with Developmental Impairment

Show evidence (2 references)

PMID:34698933 SUPPORT Human Clinical

"The seizure onset age ranged from 1 to 21 months (median age 3.75 months)."

Establishes infantile seizure onset as the clinical expression of this node.

PMID:26645412 SUPPORT Human Clinical

"Our patient presented with neonatal hypotonia and feeding difficulties, then developed pharmacoresistant epileptic encephalopathy, characterized by multiple seizure types from 3 months of age."

Illustrates the transition from an early non-seizure presentation to pharmacoresistant encephalopathy with multiple seizure types.

Drug-Resistant Epilepsy with Developmental Impairment

The clinical endpoint is chronic epilepsy that frequently resists antiseizure medication, together with global developmental delay and intellectual disability that ranges from mild to profound. Seizure control is achievable in a substantial minority — 57.7% in one cohort — and severity tracks with the variant's functional class and structural location rather than being uniform across the disease.

neuron CL:0000540

Show evidence (2 references)

PMID:34698933 SUPPORT Human Clinical

"Clinical features included cluster seizures (80.8%), fever sensitivity (53.8%), and developmental delay (96.2%)."

Quantifies the near-universal developmental delay accompanying the epilepsy.

PMID:35383156 SUPPORT Human Clinical

"Yet, patients with GABAA receptor variants have diverse clinical phenotypes and many are refractory to treatment despite the availability of drugs that enhance GABAergic activity."

Supports treatment refractoriness as a defining feature of the clinical endpoint, despite GABA-enhancing drugs being available.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

14

Musculoskeletal 1

Hypotonia HP:0001252

Show evidence (2 references)

PMID:35383156 SUPPORT Human Clinical

"The gain-of-function cohort (n = 27 patients) presented with a younger age of seizure onset, higher risk of severe intellectual disability, focal seizures at onset, hypotonia, and lower likelihood of seizure freedom in response to treatment."

Lists hypotonia among the features distinguishing the gain-of-function cohort.

PMID:26645412 SUPPORT Human Clinical

"Our patient presented with neonatal hypotonia and feeding difficulties, then developed pharmacoresistant epileptic encephalopathy, characterized by multiple seizure types from 3 months of age."

Documents neonatal hypotonia preceding seizure onset in a molecularly confirmed case.

Nervous System 11

Focal-onset seizures VERY_FREQUENT HP:0007359

Show evidence (1 reference)

PMID:34698933 SUPPORT Human Clinical

"Seizure types predominated including focal seizures (92.3%), generalized tonic-clonic seizures (23.1%), and epileptic spasms (15.4%)."

Directly quantifies focal seizures at 92.3%, supporting both the phenotype and the VERY_FREQUENT band.

Drug-resistant epilepsy Seizure HP:0001250

Show evidence (1 reference)

PMID:35383156 SUPPORT Human Clinical

"Yet, patients with GABAA receptor variants have diverse clinical phenotypes and many are refractory to treatment despite the availability of drugs that enhance GABAergic activity."

Supports treatment refractoriness in GABA-A receptor variant epilepsies including GABRB3. No frequency band is asserted because this sentence quantifies nothing.

Generalized tonic-clonic seizures OCCASIONAL Bilateral tonic-clonic seizure HP:0002069

Show evidence (1 reference)

PMID:34698933 SUPPORT Human Clinical

"Seizure types predominated including focal seizures (92.3%), generalized tonic-clonic seizures (23.1%), and epileptic spasms (15.4%)."

Quantifies generalized tonic-clonic seizures at 23.1%, mapping to the OCCASIONAL band (5-29%).

Epileptic spasms OCCASIONAL HP:0011097

Show evidence (2 references)

PMID:34698933 SUPPORT Human Clinical

"Seizure types predominated including focal seizures (92.3%), generalized tonic-clonic seizures (23.1%), and epileptic spasms (15.4%)."

Quantifies epileptic spasms at 15.4%, mapping to the OCCASIONAL band.

PMID:34698933 SUPPORT Human Clinical

"Eleven patients were diagnosed with developmental and epileptic encephalopathy (DEE), four with West syndrome, three with epilepsy of infancy with migrating focal seizures (EIMFS), one with epilepsy with myoclonic-atonic seizures (EMAS), one with Dravet syndrome, and one with febrile seizures plus (FS+)."

Documents West syndrome as one of the recognized syndromic presentations of GABRB3-related DEE.

Fever-sensitive seizures FREQUENT Febrile seizure (within the age range of 3 months to 6 years) HP:0002373

Show evidence (2 references)

PMID:34698933 SUPPORT Human Clinical

"Clinical features included cluster seizures (80.8%), fever sensitivity (53.8%), and developmental delay (96.2%)."

Quantifies fever sensitivity at 53.8%, mapping to the FREQUENT band (30-79%).

PMID:35383156 SUPPORT Human Clinical

"Febrile seizures at onset are exclusive to the loss-of-function cohort (n = 47 patients)."

Ties febrile seizures at onset specifically to the loss-of-function variant class.

Global developmental delay VERY_FREQUENT HP:0001263

Show evidence (1 reference)

PMID:34698933 SUPPORT Human Clinical

"Clinical features included cluster seizures (80.8%), fever sensitivity (53.8%), and developmental delay (96.2%)."

Quantifies developmental delay at 96.2%, supporting the VERY_FREQUENT band.

Intellectual disability HP:0001249

Show evidence (2 references)

PMID:34906499 SUPPORT Human Clinical

"Focal epilepsy with earlier onset (median: age 4 months) and severe ID were associated with variants in both the pore-lining helical transmembrane domain and the extracellular domain."

Documents severe intellectual disability and its structural-domain correlation in a 71-individual cohort.

PMID:34906499 SUPPORT Human Clinical

"Generalized epilepsy, with a median age at onset of 12 months, and mild-to-moderate ID were associated with variants in the extracellular domain."

Documents the milder end of the intellectual-disability range and its association with extracellular-domain variants.

Dystonia HP:0001332

Show evidence (1 reference)

PMID:37647766 SUPPORT Human Clinical

"This included younger age of first seizure onset (median 0.5 months), movement disorders (dystonia and dyskinesia), epilepsy of infancy with migrating focal seizures (EIMFS) and risk of early mortality."

Documents dystonia in the reduced-desensitization gain-of-function subgroup.

Dyskinesia HP:0100660

Show evidence (1 reference)

PMID:37647766 SUPPORT Human Clinical

"This included younger age of first seizure onset (median 0.5 months), movement disorders (dystonia and dyskinesia), epilepsy of infancy with migrating focal seizures (EIMFS) and risk of early mortality."

Documents dyskinesia in the reduced-desensitization gain-of-function subgroup.

Delayed myelination HP:0012448

Show evidence (1 reference)

PMID:34698933 SUPPORT Human Clinical

"Neuroimaging was abnormal in 10 patients, including dysplasia of the cerebral cortex, dysplasia of the frontal and temporal cortex, delayed myelination, and corpus callosum dysplasia."

Documents delayed myelination among the abnormal neuroimaging findings.

Abnormal corpus callosum morphology HP:0001273

Show evidence (1 reference)

PMID:34698933 SUPPORT Human Clinical

"Neuroimaging was abnormal in 10 patients, including dysplasia of the cerebral cortex, dysplasia of the frontal and temporal cortex, delayed myelination, and corpus callosum dysplasia."

Documents corpus callosum dysplasia among the abnormal neuroimaging findings. The preferred_term keeps the source's wording while the term is bound to the general HPO corpus callosum morphology class, since the source does not specify agenesis versus hypoplasia.

Other 2

Multifocal epileptiform discharges HP:0010841

Show evidence (1 reference)

PMID:26645412 SUPPORT Human Clinical

"Electroencephalography demonstrated ictal generalized and interictal multifocal epileptiform abnormalities."

Directly documents interictal multifocal epileptiform discharges.

Cortical dysplasia HP:0002539

Show evidence (1 reference)

PMID:34698933 SUPPORT Human Clinical

"Neuroimaging was abnormal in 10 patients, including dysplasia of the cerebral cortex, dysplasia of the frontal and temporal cortex, delayed myelination, and corpus callosum dysplasia."

Documents cerebral cortical dysplasia among the abnormal neuroimaging findings. No frequency band is asserted: the source quantifies abnormal imaging overall (10 of 26 patients) but not the cortical-dysplasia subset, so any band here would be a derived upper bound rather than a reported figure — the same reason the two sibling findings from this sentence carry no band.

🧬

Genetic Associations

1

GABRB3 (GABRB3 (15q12) encodes the GABA-A receptor beta-3 subunit. Heterozygous, almost always de novo, variants — predominantly missense, less often nonsense or truncating — cause developmental and epileptic encephalopathy 43. Variants segregate into functionally opposite gain-of-function and loss-of-function classes that both cause encephalopathy but with distinct clinical profiles, and phenotype additionally correlates with the variant's position in the three-dimensional subunit structure (extracellular domain versus pore-lining transmembrane domain).)

Gene: GABRB3 hgnc:4083 relationship_type: CAUSATIVE variant_origin: DE_NOVO

Autosomal dominant (almost always de novo)

Show evidence (3 references)

PMID:26645412 SUPPORT Human Clinical

"Using a SureSelectXT custom multiple gene panel covering 48 early infantile epileptic encephalopathy/developmental delay genes, a novel de novo GABRB3 heterozygous missense mutation, c.860C>T (p.Thr287Ile), was identified and confirmed on Sanger sequencing."

Documents a de novo heterozygous GABRB3 missense variant causing early infantile epileptic encephalopathy.

PMID:35383156 SUPPORT Human Clinical

"Here we show that 44 pathogenic GABRB3 missense variants segregate into gain-of-function and loss-of-function groups and respective patients display distinct clinical phenotypes."

Establishes the two-class functional architecture of the GABRB3 variant landscape across 74 patients.

PMID:34906499 SUPPORT Human Clinical

"Pathogenic variants in GABRB3 have been associated with a spectrum of phenotypes from severe developmental disorders and epileptic encephalopathies to milder epilepsy syndromes and mild intellectual disability (ID)."

Summarizes the allelic spectrum of GABRB3, of which this entry curates the encephalopathic end.

💊

Medical Actions

5

Broad-spectrum antiseizure medication (valproate, levetiracetam, perampanel)

Action: Pharmacotherapy NCIT:C15986

Agent: valproic acid CHEBI:39867 levetiracetam CHEBI:6437 perampanel CHEBI:71013

Conventional antiseizure medications remain the mainstay, usually as polytherapy. In a 26-patient cohort, seizures were controlled in 57.7% of patients, most often with valproate, levetiracetam, or perampanel, so drug-resistance is common but far from universal.

Mechanism Target:

INHIBITS Neuronal Hyperexcitability and Thalamocortical Hypersynchrony — These agents act downstream of the receptor lesion, suppressing network hyperexcitability rather than correcting the GABA-A receptor defect.

Show evidence (1 reference)

PMID:34698933 SUPPORT Human Clinical

"Seizures were controlled in 57.7% of patients by valproate, levetiracetam, or perampanel in the majority."

Shows these agents suppress the seizure output of the hyperexcitable network in a majority of the patients who achieved control, without addressing the receptor lesion itself.

Show evidence (2 references)

PMID:34698933 SUPPORT Human Clinical

"Seizures were controlled in 57.7% of patients by valproate, levetiracetam, or perampanel in the majority."

Directly reports the agents most often associated with seizure control and the proportion of patients controlled.

PMID:34698933 SUPPORT Human Clinical

"Valproate, levetiracetam and perampanel seem to have positive effects on seizure control for patients with GABRB3 variants."

The authors' own summary of which agents appear effective in GABRB3-related epilepsy.

Vigabatrin (variant-class dependent — contraindicated in gain-of-function)

Action: Pharmacotherapy NCIT:C15986

Agent: vigabatrin CHEBI:63638

Vigabatrin inhibits GABA transaminase and thereby raises tonic GABAergic current. Its effect in GABRB3-related DEE depends on which functional class the variant belongs to, and getting this wrong is harmful rather than merely ineffective. In loss-of-function variants it is expected to be safe and effective and a truncating-variant patient responded well. In gain-of-function variants it produces a hypersensitivity reaction with hypotonia, sedation, and respiratory suppression, because it further exaggerates an already excessive tonic current. Functional or structural classification of the variant should therefore precede a vigabatrin trial.

Mechanism Target:

RESTORES Loss-of-Function Reduction in GABA-A Receptor Function — By raising ambient GABA, vigabatrin compensates for reduced GABA-gated current in loss-of-function variants. The same action is the reason it is hazardous in gain-of-function variants.

Show evidence (1 reference)

PMID:33585817 SUPPORT Other

"In contrast, drug strategies increasing tonic currents in loss-of-function variants are likely to be a safe and effective therapy."

States that raising tonic current is the appropriate corrective strategy specifically for loss-of-function variants. Evidence source is OTHER because this is the authors' therapeutic recommendation inferred from their electrophysiology, not a measured clinical or in vitro result.

Show evidence (2 references)

PMID:33585817 SUPPORT Human Clinical

"However, vigabatrin, a drug that inhibits γ-aminobutyric acid transaminase to increase tonic γ-aminobutyric acid currents, has mixed success in treating seizures in patients with GABRB3 variants: some patients experience seizure cessation, but there is hypersensitivity in some patients..."

Documents both the benefit and the specific adverse reaction — hypotonia, sedation, respiratory suppression — that make vigabatrin variant-class dependent.

PMID:33585817 SUPPORT In Vitro

"We therefore propose that the hypersensitivity reaction to vigabatrin is a result of GABRB3 variants that exacerbate GABAergic tonic currents and caution is required when prescribing vigabatrin."

Gives the mechanistic reason for the contraindication in gain-of-function variants and the explicit prescribing caution.

Benzodiazepines (nitrazepam, clonazepam)

Action: Pharmacotherapy NCIT:C15986

Agent: nitrazepam CHEBI:7581 clonazepam CHEBI:3756

Benzodiazepines are also GABA-potentiating, but they act predominantly on phasic synaptic currents rather than the tonic extrasynaptic currents that vigabatrin raises — which is the mechanistic reason they were tolerated by a gain-of-function patient who could not tolerate vigabatrin. A patient with the gain-of-function p.Glu77Lys variant stabilized on nitrazepam plus the ketogenic diet, and a separate case report describes complete seizure cessation on clonazepam.

Mechanism Target:

MODULATES Disrupted Excitation-Inhibition Balance in Developing Networks — Positive allosteric modulation of synaptic GABA-A receptors prolongs inhibitory postsynaptic currents, acting on the phasic rather than the tonic compartment.

Show evidence (1 reference)

PMID:33585817 SUPPORT In Vitro

"Benzodiazepines, including nitrazepam, are positive allosteric modulators of GABAA receptors that predominately affect phasic currents, usually through prolonging inhibitory postsynaptic currents"

Specifies the compartment (phasic, not tonic) in which benzodiazepines modulate inhibitory signalling, which is why they act on this node without the vigabatrin hazard.

Show evidence (3 references)

PMID:33585817 SUPPORT In Vitro

"Benzodiazepines, including nitrazepam, are positive allosteric modulators of GABAA receptors that predominately affect phasic currents, usually through prolonging inhibitory postsynaptic currents"

Gives the pharmacological basis for why benzodiazepines behave differently from vigabatrin in gain-of-function patients.

PMID:33585817 SUPPORT Human Clinical

"She was subsequently stabilized and spasms ceased on a combination of nitrazepam and the ketogenic diet."

Documents clinical stabilization on nitrazepam plus ketogenic diet in a vigabatrin-hypersensitive gain-of-function patient.

PMID:29390378 SUPPORT Human Clinical

"Our finding suggested that clonazepam might be a choice for patient with GABRB3-related EOEE."

Single-case evidence that clonazepam can control seizures in GABRB3-related early-onset epileptic encephalopathy.

Ketogenic diet

Action: ketogenic diet Ontology label: Dietary Intervention NCIT:C15447

The ketogenic diet is used as an adjunct in refractory GABRB3-related epilepsy; it contributed to seizure cessation in combination with nitrazepam in a vigabatrin-hypersensitive gain-of-function patient.

Show evidence (1 reference)

PMID:33585817 SUPPORT Human Clinical

"She was subsequently stabilized and spasms ceased on a combination of nitrazepam and the ketogenic diet."

Supports adjunctive use of the ketogenic diet. Marked PARTIAL because the diet was given with nitrazepam in a single patient, so its independent contribution cannot be separated.

Cannabidiol (preclinical)

Action: Pharmacotherapy NCIT:C15986

Agent: cannabidiol CHEBI:69478

Cannabidiol reduced both atypical absence seizures and epileptic spasms in the Gabrb3 D120N knock-in mouse, which models a human Lennox-Gastaut-phenotype GABRB3 variant. This is a mouse-model result in a single modelled variant and has not been tested clinically in GABRB3-related DEE, so it is recorded as a preclinical rationale rather than as an established therapy.

Show evidence (2 references)

PMID:42274296 SUPPORT Model Organism

"CBD and vigabatrin significantly reduced spasm frequency compared to the vehicle."

Reports cannabidiol efficacy against epileptic spasms in the Gabrb3 D120N knock-in mouse. Evidence source is MODEL_ORGANISM; this has not been shown in patients.

PMID:32467926 SUPPORT Model Organism

"In addition, treatment with antiepileptic drugs and cannabinoids ameliorated atypical absence seizures in knock-in mice."

Independent mouse-model evidence that cannabinoids reduce atypical absence seizures in the same knock-in line.

🔬

Diagnosis

2

Trio exome/genome sequencing or epilepsy gene panel

Diagnosis is molecular: identification of a heterozygous pathogenic GABRB3 variant on a targeted epilepsy gene panel or on exome/genome sequencing, ideally in a proband-plus-parents (trio) design so that de novo status can be established. Chromosomal microarray should also be considered to exclude the mechanistically distinct 15q11.2-q13.1 deletion that also removes GABRB3.

Show evidence (1 reference)

PMID:26645412 SUPPORT Human Clinical

"Novel genetic technologies, such as whole-exome/genome sequencing and multiple gene panels, will undoubtedly identify further cases, allowing more detailed electroclinical delineation of the GABRB3-related genotypic and phenotypic spectra."

Supports gene panels and exome/genome sequencing as the diagnostic route for GABRB3-related epileptic encephalopathy.

Functional (electrophysiological) variant classification

Beyond confirming a variant, determining whether it is gain-of-function or loss-of-function has direct therapeutic consequences, because the two classes respond oppositely to drugs that raise tonic GABAergic current. Classification is done by two-electrode voltage-clamp or patch-clamp electrophysiology of the variant receptor, and the variant's structural location (extracellular domain versus pore-lining transmembrane domain) provides partial prediction when functional data are unavailable.

Show evidence (2 references)

PMID:34906499 SUPPORT Human Clinical

"These genotype-phenotype correlations will aid the genetic counseling and treatment of individuals affected by GABRB3-related disorders."

Supports using variant structural/functional classification to inform counselling and treatment.

PMID:33585817 SUPPORT In Vitro

"This study demonstrates that functional genomics can explain beneficial and adverse anti-epileptic drug effects, and propose that vigabatrin should be considered in patients with clear loss-of-function GABRB3 variants."

Directly ties functional classification of the variant to a drug-selection decision.

📊

Prevalence

1

Worldwide

Unknown Ultra Rare

No population-based prevalence or incidence estimate exists for DEE43. The disorder was only molecularly delineated from 2015 onward and the published evidence base consists of multicenter case series of tens of patients (n = 26 to 74 per series), which describe the phenotype but cannot support a population rate. The prevalence_class is recorded as the qualitative ULTRA_RARE tier rather than a numeric band for this reason.

Show evidence (1 reference)

PMID:26645412 SUPPORT Human Clinical

"GABRB3 is an emerging cause of early-onset epilepsy."

Supports the characterization of DEE43 as a recently delineated and under-ascertained cause of early-onset epilepsy. Marked PARTIAL because it supports the rarity/emerging-diagnosis framing but provides no rate.

🔀

Differential Diagnoses

4

Conditions with similar clinical presentations that must be differentiated from GABRB3-Related Developmental and Epileptic Encephalopathy:

Angelman syndrome (15q11.2-q13.1 deletion) MONDO:0007113

Overlapping Features Large maternal 15q11.2-q13.1 deletions remove GABRB3 together with UBE3A, GABRA5, GABRG3, and OCA2, and produce developmental delay, seizures, and hypotonia that overlap DEE43 clinically. The mechanism is different — a contiguous-gene deletion with UBE3A loss as the primary driver and GABRB3 co-deletion as a severity modifier — and management and counselling differ, so chromosomal microarray should be used to separate the two. Ocular hypopigmentation, long attributed to OCA2 deletion, is at least partly a GABRB3 effect: deleting Gabrb3 alone causes near-complete loss of retinal pigmentation in mice.

Show evidence (2 references)

PMID:9763493 SUPPORT Model Organism

"This study examines whether a loss or reduction in the GABAA receptor beta3 subunit (GABRB3) gene, contained within the AS deletion region, may contribute to the overall severity of AS."

Frames GABRB3 as a gene within the Angelman deletion region contributing to that syndrome's severity — the basis for the clinical overlap and for keeping the two entities distinct.

PMID:28009282 SUPPORT Model Organism

"We report here a robust phenotype in the mouse in which deletion of Gabrb3 alone causes nearly complete loss of retinal pigmentation due to atrophied melanosomes, as evidenced by electron microscopy."

Shows that GABRB3 loss alone drives ocular hypopigmentation, refining how the Angelman-region pigmentary phenotype should be attributed.

Childhood absence epilepsy MONDO:0010826

Overlapping Features GABRB3 has a long-standing association with childhood absence epilepsy, a far milder, non-encephalopathic phenotype identified through family-based association rather than through de novo pathogenic variants. It sits at the opposite end of the GABRB3 allelic spectrum from DEE43 and is deliberately outside this entry's scope.

Show evidence (1 reference)

PMID:10509183 SUPPORT Human Clinical

"The present data suggest that the tested polymorphism may be either directly involved in the etiology of CAE or in linkage disequilibrium with disease-predisposing sites."

Supports a GABRB3 association with childhood absence epilepsy. Marked PARTIAL because the authors themselves cannot distinguish direct involvement from linkage disequilibrium.

Lennox-Gastaut syndrome MONDO:0016532

Overlapping Features Lennox-Gastaut syndrome is an electroclinical syndrome diagnosis, not an alternative aetiology: a proportion of GABRB3-related DEE patients are labelled with it, and the two mouse knock-ins that model specific human GABRB3 variants (D120N, N328D) were both built to model GABRB3-associated Lennox-Gastaut syndrome. It is listed here because the syndromic label is what a patient usually carries before genetic testing, and it does not by itself identify the gene or predict the vigabatrin hazard, which depends on the variant's functional class.

Distinguishing Features

The syndromic diagnosis describes seizure semiology and EEG pattern; it does not specify aetiology, and Lennox-Gastaut syndrome has many other genetic and structural causes.
Establishing GABRB3 as the cause requires molecular testing; the gain-of-function versus loss-of-function classification of the variant then determines whether vigabatrin is appropriate or hazardous.

Show evidence (1 reference)

PMID:31435640 SUPPORT Other

"Mutations in GABRB3 have been increasingly recognized as a major cause for severe paediatric epilepsy syndromes such as Lennox-Gastaut syndrome, Dravet syndrome and infantile spasms with intellectual disability as well as relatively mild epilepsy syndromes such as childhood absence epilepsy."

Places Lennox-Gastaut syndrome among the syndromic presentations GABRB3 variants produce. Evidence source is OTHER because this sentence summarizes the field rather than reporting the study's own data.

Epilepsy of infancy with migrating focal seizures MONDO:0017385

Overlapping Features EIMFS is likewise a syndromic presentation rather than a competing aetiology, and within GABRB3 it is not randomly distributed: it marks the most severe gain-of-function subgroup, whose variants reduce receptor desensitization at equilibrium and which also carries the earliest seizure onset, movement disorder, and risk of early mortality. Three of 26 patients in one GABRB3 cohort were diagnosed with EIMFS.

Distinguishing Features

EIMFS has many genetic causes, KCNT1 being the most common; a GABRB3 cause is established only by sequencing.
Within GABRB3, an EIMFS presentation should raise suspicion of a reduced-desensitization gain-of-function variant, which is precisely the group in which vigabatrin is hazardous.

Show evidence (2 references)

PMID:37647766 SUPPORT Human Clinical

"This included younger age of first seizure onset (median 0.5 months), movement disorders (dystonia and dyskinesia), epilepsy of infancy with migrating focal seizures (EIMFS) and risk of early mortality."

Ties the EIMFS presentation to the reduced-desensitization gain-of-function subgroup rather than to GABRB3 disease generally.

PMID:34698933 SUPPORT Human Clinical

"Eleven patients were diagnosed with developmental and epileptic encephalopathy (DEE), four with West syndrome, three with epilepsy of infancy with migrating focal seizures (EIMFS), one with epilepsy with myoclonic-atonic seizures (EMAS), one with Dravet syndrome, and one with febrile seizures plus (FS+)."

Quantifies EIMFS as 3 of 26 patients in a GABRB3 cohort.

🐁

Animal Models

3

Gabrb3+/D120N knock-in Mus musculus

Heterozygous knock-in of the human de novo p.D120N Lennox-Gastaut variant. The model reproduces the human syndrome's seizure repertoire and behavioural profile and localizes the defect to inhibitory signalling in the thalamocortical loop, making it the closest available in vivo proxy for a specific human GABRB3 genotype.

Species

Mus musculus

Genotype

Gabrb3+/D120N knock-in

Genes

GABRB3 hgnc:4083

Show evidence (1 reference)

PMID:32467926 SUPPORT Model Organism

"we generated the heterozygous Gabrb3+/D120N knock-in mouse and found that it had frequent spontaneous atypical absence seizures, as well as less frequent tonic, myoclonic, atonic and generalized tonic-clonic seizures."

Describes the model and its multi-seizure-type phenotype.

Gabrb3+/N328D knock-in Mus musculus

Heterozygous knock-in of the human p.N328D Lennox-Gastaut variant, with spontaneous seizures, cognitive impairment, and reduced beta-3 subunit expression in cerebellum, hippocampus, and thalamus.

Species

Mus musculus

Genotype

Gabrb3+/N328D knock-in

Genes

GABRB3 hgnc:4083

Show evidence (1 reference)

PMID:37176165 SUPPORT Model Organism

"Gabrb3+/N328D mice showed spontaneous seizures and signs of cognitive impairment, including deficits in spatial learning, memory, and locomotion."

Documents the seizure and cognitive phenotype of the second knock-in model.

Gabrb3 null (knockout) Mus musculus

Constitutive Gabrb3 knockout. Halved brain GABA-A receptor density, severely impaired receptor function, myoclonus and epileptic seizures on EEG, high neonatal mortality with cleft palate, and an Angelman-like behavioural profile. It models the loss-of-function extreme rather than the human gain-of-function spectrum.

Species

Mus musculus

Genotype

Gabrb3 null (knockout)

Genes

GABRB3 hgnc:4083

Show evidence (2 references)

PMID:9108119 SUPPORT Model Organism

"beta3-deficient mice display frequent myoclonus and occasional epileptic seizures, documented by electroencephalographic recording."

Documents the seizure phenotype of the constitutive knockout.

PMID:9763493 SUPPORT Model Organism

"Additionally, these mice exhibited learning and memory deficits, poor motor skills on a repetitive task, hyperactivity, and a disturbed rest-activity cycle, features all common to AS."

Documents the behavioural phenotype of the knockout and its Angelman syndrome resemblance.

{ }

Source YAML

click to show

name: GABRB3-Related Developmental and Epileptic Encephalopathy
creation_date: "2026-08-08T00:00:00Z"
category: Mendelian
description: >-
  A severe early-onset developmental and epileptic encephalopathy (DEE43,
  OMIM:617113) caused by heterozygous, almost always de novo, variants in
  GABRB3, which encodes the beta-3 subunit of the GABA-A receptor — the
  pentameric ligand-gated chloride channel that mediates most fast inhibitory
  neurotransmission in the brain. Seizures usually begin in the first year of
  life, are typically multiple in type and drug-resistant, and are accompanied
  by global developmental delay and intellectual disability. The defining
  mechanistic feature of this entry is that GABRB3 variants split into two
  functionally opposite classes that both cause epileptic encephalopathy:
  loss-of-function variants reduce GABA-gated current (often through impaired
  receptor trafficking and postsynaptic clustering), while gain-of-function
  variants increase GABA potency — and, paradoxically, it is the
  gain-of-function group that has the earlier onset and the more severe
  phenotype. This is not a curiosity: it inverts the expected pharmacology, so
  that vigabatrin, a standard infantile-spasms drug that raises tonic GABAergic
  current, is beneficial in loss-of-function patients but produces a
  hypersensitivity reaction in gain-of-function patients. This entry is scoped
  to the encephalopathic (DEE43) end of the GABRB3 allelic spectrum; the milder
  GABRB3-associated phenotypes (childhood absence epilepsy, febrile seizures)
  and the mechanistically distinct 15q11.2-q13.1 contiguous-gene deletion
  (Angelman syndrome, which also removes GABRB3) are recorded as differentials
  rather than as subtypes here.
parents:
- Epilepsy
- Channelopathy
disease_term:
  preferred_term: developmental and epileptic encephalopathy, 43
  term:
    id: MONDO:0014921
    label: developmental and epileptic encephalopathy, 43
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0014921
      label: developmental and epileptic encephalopathy, 43
    mapping_predicate: skos:exactMatch
    mapping_source: MONDO
    mapping_justification: >-
      MONDO:0014921 (developmental and epileptic encephalopathy, 43;
      OMIM:617113) is the MONDO class explicitly gene-associated with GABRB3
      (RO:0004003 to hgnc:4083) and is the exact scope of this entry: the
      encephalopathic end of the GABRB3 allelic spectrum. The milder GABRB3
      phenotypes are deliberately excluded from this entry's scope and are
      recorded as differentials.
classifications:
  channelopathy_category:
    classification_value: neurological channelopathy
    evidence:
    - reference: PMID:26645412
      reference_title: "GABRB3 mutations: a new and emerging cause of early infantile epileptic encephalopathy."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Gamma‐aminobutyric acid type A (GABAA) receptors are ligand‐gated chloride channels that act as the primary mediators of fast inhibitory synaptic transmission in the central nervous system.
      explanation: >-
        The disease gene encodes a subunit of a ligand-gated chloride channel
        acting in the central nervous system, which is what makes this a
        neurological channelopathy. Evidence source is OTHER because this is
        background exposition in a case report rather than the report's own data.
  harrisons_chapter:
  - classification_value: NEUROLOGIC
    evidence:
    - reference: PMID:26645412
      reference_title: "GABRB3 mutations: a new and emerging cause of early infantile epileptic encephalopathy."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        GABRB3 is an emerging cause of early-onset epilepsy.
      explanation: >-
        Places the disorder among the epilepsies, a neurological disease class.
synonyms:
- DEE43
- EIEE43
- GABRB3 early infantile epileptic encephalopathy
- GABRB3-related epileptic encephalopathy
- epileptic encephalopathy, early infantile, 43

references:
- reference: PMID:35383156
  title: "Gain-of-function and loss-of-function GABRB3 variants lead to distinct clinical phenotypes in patients with developmental and epileptic encephalopathies."
- reference: PMID:34906499
  title: "Structural mapping of GABRB3 variants reveals genotype-phenotype correlations."
- reference: PMID:34698933
  title: "GABRB3-related epilepsy: novel variants, clinical features and therapeutic implications."
- reference: PMID:33585817
  title: "Gain-of-function GABRB3 variants identified in vigabatrin-hypersensitive epileptic encephalopathies."
- reference: PMID:37647766
  title: "Correlations of receptor desensitization of gain-of-function GABRB3 variants with clinical severity."

inheritance:
- name: Autosomal dominant (almost always de novo)
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  description: >-
    DEE43 is inherited in an autosomal dominant manner, but affected individuals
    almost always carry a de novo heterozygous variant rather than an inherited
    one. In a Chinese multicenter cohort, 25 of 26 GABRB3 variants were de novo.
    Rare inherited transmission occurs, including from a clinically unaffected
    parent; a reported nonsense variant (p.Trp2Ter) was maternally inherited.
    Because most variants are de novo, recurrence-risk counselling should
    consider the possibility of undetected parental gonadal mosaicism.
  evidence:
  - reference: PMID:34698933
    reference_title: "GABRB3-related epilepsy: novel variants, clinical features and therapeutic implications."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Thirteen GABRB3 variants were novel, and 25 were de novo.
    explanation: >-
      Quantifies the de novo fraction (25 of 26 variants) in a multicenter
      GABRB3 epilepsy cohort, supporting a dominant, predominantly de novo
      mechanism.
  - reference: PMID:29390378
    reference_title: "Early onset epileptic encephalopathy with a novel GABRB3 mutation treated effectively with clonazepam: A case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Sanger sequencing showed the mutation was present in her mother and absent in her father, indicating a maternal origin.
    explanation: >-
      Documents the exception to the de novo rule — an inherited (maternally
      transmitted) GABRB3 nonsense variant in a child with early-onset epileptic
      encephalopathy. Marked PARTIAL because a single case report establishes
      that inherited transmission occurs without quantifying how often.

prevalence:
- population: Worldwide
  measure_type: UNKNOWN
  prevalence_class: ULTRA_RARE
  notes: >-
    No population-based prevalence or incidence estimate exists for DEE43. The
    disorder was only molecularly delineated from 2015 onward and the published
    evidence base consists of multicenter case series of tens of patients
    (n = 26 to 74 per series), which describe the phenotype but cannot support a
    population rate. The prevalence_class is recorded as the qualitative
    ULTRA_RARE tier rather than a numeric band for this reason.
  evidence:
  - reference: PMID:26645412
    reference_title: "GABRB3 mutations: a new and emerging cause of early infantile epileptic encephalopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      GABRB3 is an emerging cause of early-onset epilepsy.
    explanation: >-
      Supports the characterization of DEE43 as a recently delineated and
      under-ascertained cause of early-onset epilepsy. Marked PARTIAL because it
      supports the rarity/emerging-diagnosis framing but provides no rate.

pathophysiology:
- name: GABRB3 Variant and Beta-3 Subunit Dysfunction
  role: trigger
  conforms_to: "epilepsy_excitation_inhibition_imbalance#Ion Channel and Synaptic Dysfunction"
  biological_scale: MOLECULAR
  description: >-
    A heterozygous, usually de novo, GABRB3 variant (predominantly missense,
    less often nonsense or truncating) alters the beta-3 subunit of the GABA-A
    receptor. The beta-3 subunit is highly expressed in the developing brain and
    is a component of the principal native synaptic (alpha1-beta3-gamma2) and
    extrasynaptic (alpha5-beta3-gamma2) receptor assemblies, so a single
    heterozygous variant perturbs a large fraction of brain GABA-A receptors.
  cell_types:
  - preferred_term: GABAergic neuron
    term:
      id: CL:0000617
      label: GABAergic neuron
  molecular_functions:
  - preferred_term: GABA-A receptor activity
    term:
      id: GO:0004890
      label: GABA-A receptor activity
    modifier: ABNORMAL
  cellular_components:
  - preferred_term: GABA-A receptor complex
    term:
      id: GO:1902711
      label: GABA-A receptor complex
  locations:
  - preferred_term: brain
    term:
      id: UBERON:0000955
      label: brain
  genetic_context:
    gene:
      preferred_term: GABRB3
      term:
        id: hgnc:4083
        label: GABRB3
    variant_origin: DE_NOVO
    zygosity: HETEROZYGOUS
  evidence:
  - reference: PMID:26645412
    reference_title: "GABRB3 mutations: a new and emerging cause of early infantile epileptic encephalopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The gamma-aminobutyric acid type A receptor β3 gene (GABRB3) encodes the β3-subunit of the gamma-aminobutyric acid type A (GABAA ) receptor, which mediates inhibitory signalling within the central nervous system.
    explanation: >-
      Establishes the gene product and its role as a subunit of the receptor
      mediating inhibitory signalling, the molecular starting point of this
      disease chain.
  - reference: PMID:31435640
    reference_title: "Synaptic clustering differences due to different GABRB3 mutations cause variable epilepsy syndromes."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      GABRB3 is highly expressed early in the developing brain, and its encoded β3 subunit is critical for GABAA receptor assembly and trafficking as well as stem cell differentiation in embryonic brain.
    explanation: >-
      Supports the developmental expression and assembly/trafficking role of the
      beta-3 subunit that makes a heterozygous variant consequential. Evidence
      source is OTHER because this sentence is background framing citing prior
      work rather than a result of this study's own experiments.
  downstream:
  - target: Gain-of-Function Increase in GABA Sensitivity
    description: >-
      One class of missense variants increases the potency of GABA at the mutant
      receptor.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:35383156
      reference_title: "Gain-of-function and loss-of-function GABRB3 variants lead to distinct clinical phenotypes in patients with developmental and epileptic encephalopathies."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        Here we show that 44 pathogenic GABRB3 missense variants segregate into gain-of-function and loss-of-function groups and respective patients display distinct clinical phenotypes.
      explanation: >-
        Establishes that a GABRB3 variant partitions into one of two functional
        outcomes, of which gain of function is this branch.
  - target: Loss-of-Function Reduction in GABA-A Receptor Function
    description: >-
      The other class reduces receptor function, by lowering GABA-evoked current
      or by impairing subunit assembly and delivery.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:35383156
      reference_title: "Gain-of-function and loss-of-function GABRB3 variants lead to distinct clinical phenotypes in patients with developmental and epileptic encephalopathies."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        Here we show that 44 pathogenic GABRB3 missense variants segregate into gain-of-function and loss-of-function groups and respective patients display distinct clinical phenotypes.
      explanation: >-
        Establishes the second of the two functional outcomes a GABRB3 variant
        can produce.

- name: Gain-of-Function Increase in GABA Sensitivity
  role: intermediate
  biological_scale: MOLECULAR
  description: >-
    Gain-of-function variants raise the potency of GABA at the receptor (a
    leftward shift in the GABA concentration-response relationship) without
    necessarily changing maximal open probability or absolute current. Because
    tonic, extrasynaptic inhibition is driven by low ambient GABA
    concentrations, a potency increase disproportionately amplifies tonic
    chloride flux. Counterintuitively for a receptor whose job is inhibition,
    this class carries the more severe clinical phenotype: younger seizure
    onset, higher risk of severe intellectual disability, focal seizures at
    onset, hypotonia, and lower likelihood of seizure freedom.
  molecular_functions:
  - preferred_term: GABA-A receptor activity
    term:
      id: GO:0004890
      label: GABA-A receptor activity
    modifier: GAIN_OF_FUNCTION
  biological_processes:
  - preferred_term: chloride transmembrane transport
    term:
      id: GO:1902476
      label: chloride transmembrane transport
    modifier: INCREASED
  evidence:
  - reference: PMID:35383156
    reference_title: "Gain-of-function and loss-of-function GABRB3 variants lead to distinct clinical phenotypes in patients with developmental and epileptic encephalopathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The gain-of-function cohort (n = 27 patients) presented with a younger age of seizure onset, higher risk of severe intellectual disability, focal seizures at onset, hypotonia, and lower likelihood of seizure freedom in response to treatment.
    explanation: >-
      Defines the gain-of-function class and its distinct, more severe clinical
      profile in a 74-patient cohort.
  - reference: PMID:33585817
    reference_title: "Gain-of-function GABRB3 variants identified in vigabatrin-hypersensitive epileptic encephalopathies."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Results showed an atypical gain-of-function molecular phenotype in the GABRB3 p.Glu77Lys and p.Thr287Ile variants characterized by increased potency of γ-aminobutyric acid A without change to the estimated maximum open channel probability, deactivation kinetics or absolute currents.
    explanation: >-
      Provides the electrophysiological definition of the gain-of-function
      phenotype as increased GABA potency rather than increased maximal current.
  downstream:
  - target: Altered Receptor Desensitization
    description: >-
      Within the gain-of-function class, desensitization kinetics further tune
      how much excess chloride flux persists at equilibrium.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:37647766
      reference_title: "Correlations of receptor desensitization of gain-of-function GABRB3 variants with clinical severity."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        Of the 20 gain-of-function variants assessed, 13 were found to alter receptor desensitization properties.
      explanation: >-
        Shows that most gain-of-function variants additionally alter
        desensitization, supporting this edge from the gain-of-function node to
        the desensitization modifier.
  - target: Disrupted Excitation-Inhibition Balance in Developing Networks
    description: >-
      Excess tonic GABAergic conductance in immature cortical and thalamocortical
      circuits disturbs, rather than restores, network balance.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    hypothesis_groups:
    - gof_tonic_current_excess
    evidence:
    - reference: PMID:33585817
      reference_title: "Gain-of-function GABRB3 variants identified in vigabatrin-hypersensitive epileptic encephalopathies."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        Modelling of the activation properties of the receptors indicated that either variant caused increased chloride flux in response to low concentrations of γ-aminobutyric acid that mediate tonic currents.
      explanation: >-
        Provides the mechanistic step from increased GABA potency to excess tonic
        chloride flux, the change that displaces network excitation-inhibition
        balance. The link is marked INDIRECT_KNOWN_INTERMEDIATES because the
        measurement is of receptor-level flux, not of network balance itself.

- name: Altered Receptor Desensitization
  role: modifier
  biological_scale: MOLECULAR
  description: >-
    Desensitization — the decline of current during sustained agonist exposure —
    is a second, independent axis of gain-of-function severity. Variants that
    reduce desensitization at equilibrium sustain the excess conductance and
    worsen gain-of-function traits; these cluster in the pore-forming
    transmembrane region and are associated with the most severe outcomes
    (median first-seizure onset 0.5 months, movement disorder, migrating focal
    seizures, and risk of early mortality). Variants that instead accelerate
    current decay limit the gain-of-function effect, cluster in the activation
    coupling loops, and are associated with later onset and milder phenotypes.
  molecular_functions:
  - preferred_term: GABA-A receptor activity
    term:
      id: GO:0004890
      label: GABA-A receptor activity
    modifier: ABNORMAL
  evidence:
  - reference: PMID:37647766
    reference_title: "Correlations of receptor desensitization of gain-of-function GABRB3 variants with clinical severity."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Of the 20 gain-of-function variants assessed, 13 were found to alter receptor desensitization properties. Seven variants reduced desensitization at equilibrium, which acts to worsen gain-of-function traits. Six variants accelerated current decay kinetics, which limits gain-of-function traits.
    explanation: >-
      Establishes desensitization as a distinct modifier of the gain-of-function
      molecular phenotype, in two opposite directions.
  - reference: PMID:37647766
    reference_title: "Correlations of receptor desensitization of gain-of-function GABRB3 variants with clinical severity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This included younger age of first seizure onset (median 0.5 months), movement disorders (dystonia and dyskinesia), epilepsy of infancy with migrating focal seizures (EIMFS) and risk of early mortality.
    explanation: >-
      Links reduced desensitization at equilibrium to the most severe clinical
      subgroup, including movement disorder and early-mortality risk.
  downstream:
  - target: Disrupted Excitation-Inhibition Balance in Developing Networks
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:37647766
      reference_title: "Correlations of receptor desensitization of gain-of-function GABRB3 variants with clinical severity."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        Variants that reduced the desensitization at equilibrium were clustered in the transmembrane regions that constitute the channel pore and correlated with greater disease severity, while variants that accelerated current decay were clustered in the coupling loops responsible for receptor activation and correlated with lesser severity.
      explanation: >-
        Ties the direction of the desensitization change to the magnitude of
        downstream disease severity, supporting desensitization as a modifier of
        the network-level consequence.

- name: Loss-of-Function Reduction in GABA-A Receptor Function
  role: intermediate
  biological_scale: MOLECULAR
  description: >-
    The other functional class reduces GABA-A receptor function, the mechanism
    originally presumed to account for all GABA-A receptor epilepsies. These
    patients have a distinct clinical signature: febrile seizures at onset occur
    exclusively in this group, and treatment response is comparatively better.
  molecular_functions:
  - preferred_term: GABA-A receptor activity
    term:
      id: GO:0004890
      label: GABA-A receptor activity
    modifier: LOSS_OF_FUNCTION
  biological_processes:
  - preferred_term: inhibitory postsynaptic potential
    term:
      id: GO:0060080
      label: inhibitory postsynaptic potential
    modifier: DECREASED
  evidence:
  - reference: PMID:35383156
    reference_title: "Gain-of-function and loss-of-function GABRB3 variants lead to distinct clinical phenotypes in patients with developmental and epileptic encephalopathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Febrile seizures at onset are exclusive to the loss-of-function cohort (n = 47 patients).
    explanation: >-
      Defines the loss-of-function class as a separable cohort with its own
      clinical onset signature.
  - reference: PMID:35383156
    reference_title: "Gain-of-function and loss-of-function GABRB3 variants lead to distinct clinical phenotypes in patients with developmental and epileptic encephalopathies."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      These variants are presumed to cause loss-of-function receptors leading to reduced neuronal GABAergic activity.
    explanation: >-
      States the prior assumption that GABA-A receptor epilepsy variants act by
      loss of function — the framing this entry's two-class model revises.
      Evidence source is OTHER because this sentence states the field's
      background assumption rather than reporting the study's own data.
  downstream:
  - target: Impaired Receptor Trafficking and Postsynaptic Clustering
    description: >-
      A recurrent cellular route to loss of function is failure to deliver and
      retain receptors at inhibitory synapses.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:31435640
      reference_title: "Synaptic clustering differences due to different GABRB3 mutations cause variable epilepsy syndromes."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        This suggests that impaired receptor localization to synapses is a common pathophysiological mechanism for GABRB3 mutations, although the extent of impairment may be different among mutant subunits.
      explanation: >-
        Identifies impaired synaptic receptor localization as the common cellular
        route by which GABRB3 variants lose function.
  - target: Disrupted Excitation-Inhibition Balance in Developing Networks
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:9108119
      reference_title: "Mice devoid of gamma-aminobutyrate type A receptor beta3 subunit have epilepsy, cleft palate, and hypersensitive behavior."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        Hyperactivity, lack of coordination, and seizures are consistent with reduced presynaptic inhibition in spinal cord and impaired inhibition in higher cortical centers and/or pleiotropic developmental defects.
      explanation: >-
        Attributes the in vivo consequences of beta-3 subunit loss to impaired
        inhibition in cortical centres, the network-balance node.

- name: Impaired Receptor Trafficking and Postsynaptic Clustering
  role: intermediate
  biological_scale: CELLULAR
  description: >-
    Mutant beta-3 subunits reduce surface and synaptic receptor levels and, more
    strikingly, act in trans on the wild-type receptor pool: they impair
    postsynaptic clustering of wild-type gamma-2 subunits and prevent gamma-2
    from being incorporated into synaptic GABA-A receptors. Because gamma-2 is
    what anchors GABA-A receptors at the synapse, this converts a heterozygous
    subunit defect into a broader loss of synaptic inhibitory receptors. The same
    reduction in synaptic gamma-2 clustering is seen in Gabrb3 heterozygous
    knockout mice.
  cell_types:
  - preferred_term: GABAergic neuron
    term:
      id: CL:0000617
      label: GABAergic neuron
  biological_processes:
  - preferred_term: GABA-A receptor localization to the plasma membrane
    term:
      id: GO:0072659
      label: protein localization to plasma membrane
    modifier: DECREASED
  cellular_components:
  - preferred_term: GABA-ergic synapse
    term:
      id: GO:0098982
      label: GABA-ergic synapse
  evidence:
  - reference: PMID:31435640
    reference_title: "Synaptic clustering differences due to different GABRB3 mutations cause variable epilepsy syndromes."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Interestingly, both mutant β3 subunits impaired postsynaptic clustering of wild-type GABAA receptor γ2 subunits and prevented γ2 subunits from incorporating into GABAA receptors at synapses, although by different cellular mechanisms.
    explanation: >-
      Demonstrates the trans-acting clustering defect by which mutant beta-3
      subunits deplete synaptic receptors beyond simple haploinsufficiency.
  - reference: PMID:31435640
    reference_title: "Synaptic clustering differences due to different GABRB3 mutations cause variable epilepsy syndromes."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      This suggests that impaired receptor localization to synapses is a common pathophysiological mechanism for GABRB3 mutations, although the extent of impairment may be different among mutant subunits.
    explanation: >-
      Generalizes impaired synaptic localization as a shared cellular mechanism
      across GABRB3 variants, with variant-dependent severity.
  - reference: PMID:31435640
    reference_title: "Synaptic clustering differences due to different GABRB3 mutations cause variable epilepsy syndromes."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Importantly, wild-type γ2 subunits were reduced and less clustered at inhibitory synapses in Gabrb3+/- knockout mice.
    explanation: >-
      Confirms the synaptic clustering deficit in vivo in a heterozygous Gabrb3
      mouse, showing it is not an artifact of heterologous expression.
  downstream:
  - target: Disrupted Excitation-Inhibition Balance in Developing Networks
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:31435640
      reference_title: "Synaptic clustering differences due to different GABRB3 mutations cause variable epilepsy syndromes."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        Importantly, wild-type γ2 subunits were reduced and less clustered at inhibitory synapses in Gabrb3+/- knockout mice.
      explanation: >-
        Shows in vivo that the clustering defect depletes receptors at inhibitory
        synapses, which is what reduces inhibitory drive at the network node.

- name: Disrupted Excitation-Inhibition Balance in Developing Networks
  role: amplifier
  conforms_to: "epilepsy_excitation_inhibition_imbalance#Excitation-Inhibition Imbalance"
  biological_scale: CELLULAR
  description: >-
    Both functional classes converge here. GABA-A receptor signalling in
    developing cortical, hippocampal, and thalamocortical circuits is displaced
    from its normal set point — reduced in loss-of-function variants, excessive
    and mistimed (particularly in the tonic, extrasynaptic compartment) in
    gain-of-function variants. Either displacement destabilizes the balance
    between excitation and inhibition. In the Gabrb3 D120N knock-in mouse this
    manifests as reduced miniature inhibitory postsynaptic current amplitude in
    cortical neurons and prolonged spontaneous thalamocortical oscillations.
  cell_types:
  - preferred_term: GABAergic neuron
    term:
      id: CL:0000617
      label: GABAergic neuron
  - preferred_term: pyramidal neuron
    term:
      id: CL:0000598
      label: pyramidal neuron
  biological_processes:
  - preferred_term: gamma-aminobutyric acid signaling pathway
    term:
      id: GO:0007214
      label: gamma-aminobutyric acid signaling pathway
    modifier: ABNORMAL
  - preferred_term: synaptic transmission, GABAergic
    term:
      id: GO:0051932
      label: synaptic transmission, GABAergic
    modifier: ABNORMAL
  locations:
  - preferred_term: brain
    term:
      id: UBERON:0000955
      label: brain
  evidence:
  - reference: PMID:32467926
    reference_title: "GABA(A) receptor β3 subunit mutation D120N causes Lennox-Gastaut syndrome in knock-in mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      However, cortical neurons in thalamocortical slices from knock-in mice had reduced miniature inhibitory post-synaptic current amplitude and prolonged spontaneous thalamocortical oscillations.
    explanation: >-
      Provides direct circuit-level evidence that a disease-causing GABRB3
      variant shifts inhibitory synaptic drive and prolongs thalamocortical
      oscillations.
  - reference: PMID:32467926
    reference_title: "GABA(A) receptor β3 subunit mutation D120N causes Lennox-Gastaut syndrome in knock-in mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Thus, the Gabrb3+/D120N knock-in mouse recapitulated human Lennox-Gastaut syndrome seizure types and behavioural abnormalities and was caused by impaired inhibitory GABAergic signalling in the thalamocortical loop.
    explanation: >-
      Attributes the modelled human seizure phenotype specifically to impaired
      inhibitory GABAergic signalling in the thalamocortical loop.
  - reference: PMID:9108119
    reference_title: "Mice devoid of gamma-aminobutyrate type A receptor beta3 subunit have epilepsy, cleft palate, and hypersensitive behavior."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      GABA(A)-R density is approximately halved in brain of beta3-deficient mice, and GABA(A)-R function is severely impaired.
    explanation: >-
      Shows that removing the beta-3 subunit halves brain GABA-A receptor density
      and severely impairs receptor function, the loss-of-function extreme of
      this node.
  downstream:
  - target: Neuronal Hyperexcitability and Thalamocortical Hypersynchrony
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:32467926
      reference_title: "GABA(A) receptor β3 subunit mutation D120N causes Lennox-Gastaut syndrome in knock-in mice."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        However, cortical neurons in thalamocortical slices from knock-in mice had reduced miniature inhibitory post-synaptic current amplitude and prolonged spontaneous thalamocortical oscillations.
      explanation: >-
        Couples the reduction in inhibitory synaptic drive directly to prolonged
        hypersynchronous thalamocortical oscillations in the same preparation.

- name: Neuronal Hyperexcitability and Thalamocortical Hypersynchrony
  role: central_effector
  conforms_to: "epilepsy_excitation_inhibition_imbalance#Neuronal Hyperexcitability and Hypersynchrony"
  biological_scale: TISSUE
  description: >-
    The destabilized network fires excessively and synchronously. In patients
    this is visible as ictal generalized and interictal multifocal epileptiform
    abnormalities on EEG; in the D120N knock-in mouse it appears as prolonged
    spontaneous thalamocortical oscillations underlying atypical absence
    seizures.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: action potential
    term:
      id: GO:0001508
      label: action potential
    modifier: INCREASED
  locations:
  - preferred_term: brain
    term:
      id: UBERON:0000955
      label: brain
  evidence:
  - reference: PMID:26645412
    reference_title: "GABRB3 mutations: a new and emerging cause of early infantile epileptic encephalopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Electroencephalography demonstrated ictal generalized and interictal multifocal epileptiform abnormalities.
    explanation: >-
      Documents the hypersynchronous discharges in a molecularly confirmed
      GABRB3 patient.
  - reference: PMID:9763493
    reference_title: "Mice lacking the beta3 subunit of the GABAA receptor have the epilepsy phenotype and many of the behavioral characteristics of Angelman syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Disrupting the gabrb3 gene in mice produces electroencephalographic abnormalities, seizures, and behavior that parallel those seen in AS.
    explanation: >-
      Shows that beta-3 subunit disruption alone is sufficient to produce
      electroencephalographic abnormality and seizures in vivo.
  downstream:
  - target: Seizure Generation and Developmental Encephalopathy
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:26645412
      reference_title: "GABRB3 mutations: a new and emerging cause of early infantile epileptic encephalopathy."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Electroencephalography demonstrated ictal generalized and interictal multifocal epileptiform abnormalities.
      explanation: >-
        Links the hypersynchronous discharges recorded on EEG to the clinical
        ictal events they accompany in a molecularly confirmed patient.

- name: Seizure Generation and Developmental Encephalopathy
  role: effector
  conforms_to: "epilepsy_excitation_inhibition_imbalance#Seizure Generation and Epileptogenesis"
  biological_scale: ORGANISM
  description: >-
    Hypersynchronous discharges become clinical seizures, typically starting in
    the first year of life and typically of several types in the same child.
    Because the same receptor defect that generates seizures also disturbs
    GABAergic signalling during a period when it is shaping circuit development,
    the developmental impairment is not simply a consequence of seizure burden —
    which is what the "developmental and epileptic encephalopathy" designation
    is intended to capture.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:34698933
    reference_title: "GABRB3-related epilepsy: novel variants, clinical features and therapeutic implications."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The seizure onset age ranged from 1 to 21 months (median age 3.75 months).
    explanation: >-
      Establishes infantile seizure onset as the clinical expression of this
      node.
  - reference: PMID:26645412
    reference_title: "GABRB3 mutations: a new and emerging cause of early infantile epileptic encephalopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Our patient presented with neonatal hypotonia and feeding difficulties, then developed pharmacoresistant epileptic encephalopathy, characterized by multiple seizure types from 3 months of age.
    explanation: >-
      Illustrates the transition from an early non-seizure presentation to
      pharmacoresistant encephalopathy with multiple seizure types.
  downstream:
  - target: Drug-Resistant Epilepsy with Developmental Impairment
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:26645412
      reference_title: "GABRB3 mutations: a new and emerging cause of early infantile epileptic encephalopathy."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Our patient presented with neonatal hypotonia and feeding difficulties, then developed pharmacoresistant epileptic encephalopathy, characterized by multiple seizure types from 3 months of age.
      explanation: >-
        Documents progression from seizure onset to established pharmacoresistant
        encephalopathy, the transition this edge represents.

- name: Drug-Resistant Epilepsy with Developmental Impairment
  role: consequence
  conforms_to: "epilepsy_excitation_inhibition_imbalance#Recurrent Unprovoked Seizures"
  biological_scale: ORGANISM
  description: >-
    The clinical endpoint is chronic epilepsy that frequently resists
    antiseizure medication, together with global developmental delay and
    intellectual disability that ranges from mild to profound. Seizure control
    is achievable in a substantial minority — 57.7% in one cohort — and severity
    tracks with the variant's functional class and structural location rather
    than being uniform across the disease.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:34698933
    reference_title: "GABRB3-related epilepsy: novel variants, clinical features and therapeutic implications."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Clinical features included cluster seizures (80.8%), fever sensitivity (53.8%), and developmental delay (96.2%).
    explanation: >-
      Quantifies the near-universal developmental delay accompanying the
      epilepsy.
  - reference: PMID:35383156
    reference_title: "Gain-of-function and loss-of-function GABRB3 variants lead to distinct clinical phenotypes in patients with developmental and epileptic encephalopathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Yet, patients with GABAA receptor variants have diverse clinical phenotypes and many are refractory to treatment despite the availability of drugs that enhance GABAergic activity.
    explanation: >-
      Supports treatment refractoriness as a defining feature of the clinical
      endpoint, despite GABA-enhancing drugs being available.

mechanistic_hypotheses:
- hypothesis_group_id: gof_tonic_current_excess
  hypothesis_label: >-
    Gain-of-function severity arises from excess tonic (extrasynaptic) GABAergic
    current during development
  status: EMERGING
  description: >-
    Under this model, the reason gain-of-function GABRB3 variants cause the more
    severe encephalopathy is that increased GABA potency preferentially
    amplifies tonic currents carried by extrasynaptic receptors responding to
    low ambient GABA. Excess tonic inhibition during the period when GABAergic
    signalling patterns developing circuits is proposed to be as damaging as too
    little. The strongest support is pharmacological and indirect: vigabatrin,
    which raises tonic GABA current, produces hypotonia, sedation, and
    respiratory suppression specifically in gain-of-function patients, whereas
    benzodiazepines, which act mainly on phasic synaptic currents, do not. It is
    recorded as EMERGING rather than canonical because no study has yet measured
    the proposed tonic-current excess in patient neurons or shown that
    normalizing it reverses the phenotype.
  evidence:
  - reference: PMID:33585817
    reference_title: "Gain-of-function GABRB3 variants identified in vigabatrin-hypersensitive epileptic encephalopathies."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      We therefore propose that the hypersensitivity reaction to vigabatrin is a result of GABRB3 variants that exacerbate GABAergic tonic currents and caution is required when prescribing vigabatrin.
    explanation: >-
      States the tonic-current-excess model directly, as the proposed explanation
      for the gain-of-function vigabatrin hypersensitivity.

phenotypes:
- category: Neurologic
  name: Focal-onset seizures
  description: >-
    Focal-onset seizures are the dominant seizure type, reported in 92.3% of a
    26-patient multicenter cohort, and focal seizures at onset are specifically
    enriched in the gain-of-function group.
  phenotype_term:
    preferred_term: Focal-onset seizure
    term:
      id: HP:0007359
      label: Focal-onset seizure
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:34698933
    reference_title: "GABRB3-related epilepsy: novel variants, clinical features and therapeutic implications."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Seizure types predominated including focal seizures (92.3%), generalized tonic-clonic seizures (23.1%), and epileptic spasms (15.4%).
    explanation: >-
      Directly quantifies focal seizures at 92.3%, supporting both the phenotype
      and the VERY_FREQUENT band.

- category: Neurologic
  name: Drug-resistant epilepsy
  description: >-
    Seizures are frequently refractory to antiseizure medication and typically
    require polytherapy. Refractoriness is not uniform: it is more likely in the
    gain-of-function group, and 57.7% of one cohort achieved seizure control.
  phenotype_term:
    preferred_term: Drug-resistant seizures
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:35383156
    reference_title: "Gain-of-function and loss-of-function GABRB3 variants lead to distinct clinical phenotypes in patients with developmental and epileptic encephalopathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Yet, patients with GABAA receptor variants have diverse clinical phenotypes and many are refractory to treatment despite the availability of drugs that enhance GABAergic activity.
    explanation: >-
      Supports treatment refractoriness in GABA-A receptor variant epilepsies
      including GABRB3. No frequency band is asserted because this sentence
      quantifies nothing.

- category: Neurologic
  name: Generalized tonic-clonic seizures
  description: >-
    Bilateral tonic-clonic seizures occur in a minority of patients, reported at
    23.1% in a 26-patient cohort.
  phenotype_term:
    preferred_term: Generalized tonic-clonic seizure
    term:
      id: HP:0002069
      label: Bilateral tonic-clonic seizure
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:34698933
    reference_title: "GABRB3-related epilepsy: novel variants, clinical features and therapeutic implications."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Seizure types predominated including focal seizures (92.3%), generalized tonic-clonic seizures (23.1%), and epileptic spasms (15.4%).
    explanation: >-
      Quantifies generalized tonic-clonic seizures at 23.1%, mapping to the
      OCCASIONAL band (5-29%).

- category: Neurologic
  name: Epileptic spasms
  description: >-
    Epileptic (infantile) spasms occur in a minority of patients and may evolve
    into a West syndrome presentation; four of 26 patients in one cohort were
    diagnosed with West syndrome.
  phenotype_term:
    preferred_term: Epileptic spasm
    term:
      id: HP:0011097
      label: Epileptic spasm
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:34698933
    reference_title: "GABRB3-related epilepsy: novel variants, clinical features and therapeutic implications."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Seizure types predominated including focal seizures (92.3%), generalized tonic-clonic seizures (23.1%), and epileptic spasms (15.4%).
    explanation: >-
      Quantifies epileptic spasms at 15.4%, mapping to the OCCASIONAL band.
  - reference: PMID:34698933
    reference_title: "GABRB3-related epilepsy: novel variants, clinical features and therapeutic implications."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Eleven patients were diagnosed with developmental and epileptic encephalopathy (DEE), four with West syndrome, three with epilepsy of infancy with migrating focal seizures (EIMFS), one with epilepsy with myoclonic-atonic seizures (EMAS), one with Dravet syndrome, and one with febrile seizures plus (FS+).
    explanation: >-
      Documents West syndrome as one of the recognized syndromic presentations of
      GABRB3-related DEE.

- category: Neurologic
  name: Fever-sensitive seizures
  description: >-
    Seizures are triggered or exacerbated by fever in roughly half of patients.
    Febrile seizures specifically at epilepsy onset are a signature of the
    loss-of-function class.
  phenotype_term:
    preferred_term: Febrile seizure
    term:
      id: HP:0002373
      label: Febrile seizure (within the age range of 3 months to 6 years)
  frequency: FREQUENT
  evidence:
  - reference: PMID:34698933
    reference_title: "GABRB3-related epilepsy: novel variants, clinical features and therapeutic implications."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Clinical features included cluster seizures (80.8%), fever sensitivity (53.8%), and developmental delay (96.2%).
    explanation: >-
      Quantifies fever sensitivity at 53.8%, mapping to the FREQUENT band
      (30-79%).
  - reference: PMID:35383156
    reference_title: "Gain-of-function and loss-of-function GABRB3 variants lead to distinct clinical phenotypes in patients with developmental and epileptic encephalopathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Febrile seizures at onset are exclusive to the loss-of-function cohort (n = 47 patients).
    explanation: >-
      Ties febrile seizures at onset specifically to the loss-of-function variant
      class.

- category: Neurologic
  name: Global developmental delay
  description: >-
    Global developmental delay is near-universal, reported in 96.2% of a
    26-patient cohort.
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:34698933
    reference_title: "GABRB3-related epilepsy: novel variants, clinical features and therapeutic implications."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Clinical features included cluster seizures (80.8%), fever sensitivity (53.8%), and developmental delay (96.2%).
    explanation: >-
      Quantifies developmental delay at 96.2%, supporting the VERY_FREQUENT band.

- category: Neurologic
  name: Intellectual disability
  description: >-
    Intellectual disability ranges from mild to severe. Severity is not random:
    severe intellectual disability is enriched in the gain-of-function group and
    in patients with pore-lining transmembrane-domain variants, whereas
    extracellular-domain variants are associated with mild-to-moderate
    impairment.
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: PMID:34906499
    reference_title: "Structural mapping of GABRB3 variants reveals genotype-phenotype correlations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Focal epilepsy with earlier onset (median: age 4 months) and severe ID were associated with variants in both the pore-lining helical transmembrane domain and the extracellular domain.
    explanation: >-
      Documents severe intellectual disability and its structural-domain
      correlation in a 71-individual cohort.
  - reference: PMID:34906499
    reference_title: "Structural mapping of GABRB3 variants reveals genotype-phenotype correlations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Generalized epilepsy, with a median age at onset of 12 months, and mild-to-moderate ID were associated with variants in the extracellular domain.
    explanation: >-
      Documents the milder end of the intellectual-disability range and its
      association with extracellular-domain variants.

- category: Neurologic
  name: Hypotonia
  description: >-
    Hypotonia is a recognized feature and is specifically enriched in the
    gain-of-function group; it may also precede seizure onset, as in a reported
    patient with neonatal hypotonia and feeding difficulties.
  phenotype_term:
    preferred_term: Hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
  evidence:
  - reference: PMID:35383156
    reference_title: "Gain-of-function and loss-of-function GABRB3 variants lead to distinct clinical phenotypes in patients with developmental and epileptic encephalopathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The gain-of-function cohort (n = 27 patients) presented with a younger age of seizure onset, higher risk of severe intellectual disability, focal seizures at onset, hypotonia, and lower likelihood of seizure freedom in response to treatment.
    explanation: >-
      Lists hypotonia among the features distinguishing the gain-of-function
      cohort.
  - reference: PMID:26645412
    reference_title: "GABRB3 mutations: a new and emerging cause of early infantile epileptic encephalopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Our patient presented with neonatal hypotonia and feeding difficulties, then developed pharmacoresistant epileptic encephalopathy, characterized by multiple seizure types from 3 months of age.
    explanation: >-
      Documents neonatal hypotonia preceding seizure onset in a molecularly
      confirmed case.

- category: Neurologic
  name: Dystonia
  description: >-
    Dystonia occurs in the most severe gain-of-function subgroup — those whose
    variants reduce receptor desensitization at equilibrium — alongside the
    earliest seizure onset and risk of early mortality. It is not a feature of
    the milder gain-of-function subgroup whose variants accelerate current decay.
  phenotype_term:
    preferred_term: Dystonia
    term:
      id: HP:0001332
      label: Dystonia
  evidence:
  - reference: PMID:37647766
    reference_title: "Correlations of receptor desensitization of gain-of-function GABRB3 variants with clinical severity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This included younger age of first seizure onset (median 0.5 months), movement disorders (dystonia and dyskinesia), epilepsy of infancy with migrating focal seizures (EIMFS) and risk of early mortality.
    explanation: >-
      Documents dystonia in the reduced-desensitization gain-of-function
      subgroup.

- category: Neurologic
  name: Dyskinesia
  description: >-
    Dyskinesia accompanies dystonia in the reduced-desensitization
    gain-of-function subgroup.
  phenotype_term:
    preferred_term: Dyskinesia
    term:
      id: HP:0100660
      label: Dyskinesia
  evidence:
  - reference: PMID:37647766
    reference_title: "Correlations of receptor desensitization of gain-of-function GABRB3 variants with clinical severity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This included younger age of first seizure onset (median 0.5 months), movement disorders (dystonia and dyskinesia), epilepsy of infancy with migrating focal seizures (EIMFS) and risk of early mortality.
    explanation: >-
      Documents dyskinesia in the reduced-desensitization gain-of-function
      subgroup.

- category: Neurologic
  name: Multifocal epileptiform discharges
  description: >-
    Interictal EEG shows multifocal epileptiform abnormalities, with generalized
    ictal patterns.
  phenotype_term:
    preferred_term: Multifocal epileptiform discharges
    term:
      id: HP:0010841
      label: Multifocal epileptiform discharges
  evidence:
  - reference: PMID:26645412
    reference_title: "GABRB3 mutations: a new and emerging cause of early infantile epileptic encephalopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Electroencephalography demonstrated ictal generalized and interictal multifocal epileptiform abnormalities.
    explanation: >-
      Directly documents interictal multifocal epileptiform discharges.

- category: Neurologic
  name: Cortical dysplasia
  description: >-
    Brain MRI is often normal, but a minority of patients have structural
    abnormalities; cortical dysplasia was among the findings in 10 of 26
    patients with abnormal neuroimaging in one cohort.
  phenotype_term:
    preferred_term: Cortical dysplasia
    term:
      id: HP:0002539
      label: Cortical dysplasia
  evidence:
  - reference: PMID:34698933
    reference_title: "GABRB3-related epilepsy: novel variants, clinical features and therapeutic implications."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Neuroimaging was abnormal in 10 patients, including dysplasia of the cerebral cortex, dysplasia of the frontal and temporal cortex, delayed myelination, and corpus callosum dysplasia.
    explanation: >-
      Documents cerebral cortical dysplasia among the abnormal neuroimaging
      findings. No frequency band is asserted: the source quantifies abnormal
      imaging overall (10 of 26 patients) but not the cortical-dysplasia subset,
      so any band here would be a derived upper bound rather than a reported
      figure — the same reason the two sibling findings from this sentence carry
      no band.

- category: Neurologic
  name: Delayed myelination
  description: >-
    Delayed myelination is one of the reported structural MRI abnormalities.
  phenotype_term:
    preferred_term: Delayed myelination
    term:
      id: HP:0012448
      label: Delayed myelination
  evidence:
  - reference: PMID:34698933
    reference_title: "GABRB3-related epilepsy: novel variants, clinical features and therapeutic implications."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Neuroimaging was abnormal in 10 patients, including dysplasia of the cerebral cortex, dysplasia of the frontal and temporal cortex, delayed myelination, and corpus callosum dysplasia.
    explanation: >-
      Documents delayed myelination among the abnormal neuroimaging findings.

- category: Neurologic
  name: Abnormal corpus callosum morphology
  description: >-
    Corpus callosum dysplasia is one of the reported structural MRI
    abnormalities.
  phenotype_term:
    preferred_term: Corpus callosum dysplasia
    term:
      id: HP:0001273
      label: Abnormal corpus callosum morphology
  evidence:
  - reference: PMID:34698933
    reference_title: "GABRB3-related epilepsy: novel variants, clinical features and therapeutic implications."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Neuroimaging was abnormal in 10 patients, including dysplasia of the cerebral cortex, dysplasia of the frontal and temporal cortex, delayed myelination, and corpus callosum dysplasia.
    explanation: >-
      Documents corpus callosum dysplasia among the abnormal neuroimaging
      findings. The preferred_term keeps the source's wording while the term is
      bound to the general HPO corpus callosum morphology class, since the source
      does not specify agenesis versus hypoplasia.

genetic:
- name: GABRB3
  gene_term:
    preferred_term: GABRB3
    term:
      id: hgnc:4083
      label: GABRB3
  association: >-
    GABRB3 (15q12) encodes the GABA-A receptor beta-3 subunit. Heterozygous,
    almost always de novo, variants — predominantly missense, less often
    nonsense or truncating — cause developmental and epileptic encephalopathy
    43. Variants segregate into functionally opposite gain-of-function and
    loss-of-function classes that both cause encephalopathy but with distinct
    clinical profiles, and phenotype additionally correlates with the variant's
    position in the three-dimensional subunit structure (extracellular domain
    versus pore-lining transmembrane domain).
  relationship_type: CAUSATIVE
  variant_origin: DE_NOVO
  inheritance:
  - name: Autosomal dominant (almost always de novo)
    evidence:
    - reference: PMID:34698933
      reference_title: "GABRB3-related epilepsy: novel variants, clinical features and therapeutic implications."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Thirteen GABRB3 variants were novel, and 25 were de novo.
      explanation: >-
        Supports the dominant, predominantly de novo mode of inheritance for
        pathogenic GABRB3 variants.
  evidence:
  - reference: PMID:26645412
    reference_title: "GABRB3 mutations: a new and emerging cause of early infantile epileptic encephalopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Using a SureSelectXT custom multiple gene panel covering 48 early infantile epileptic encephalopathy/developmental delay genes, a novel de novo GABRB3 heterozygous missense mutation, c.860C>T (p.Thr287Ile), was identified and confirmed on Sanger sequencing.
    explanation: >-
      Documents a de novo heterozygous GABRB3 missense variant causing early
      infantile epileptic encephalopathy.
  - reference: PMID:35383156
    reference_title: "Gain-of-function and loss-of-function GABRB3 variants lead to distinct clinical phenotypes in patients with developmental and epileptic encephalopathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Here we show that 44 pathogenic GABRB3 missense variants segregate into gain-of-function and loss-of-function groups and respective patients display distinct clinical phenotypes.
    explanation: >-
      Establishes the two-class functional architecture of the GABRB3 variant
      landscape across 74 patients.
  - reference: PMID:34906499
    reference_title: "Structural mapping of GABRB3 variants reveals genotype-phenotype correlations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Pathogenic variants in GABRB3 have been associated with a spectrum of phenotypes from severe developmental disorders and epileptic encephalopathies to milder epilepsy syndromes and mild intellectual disability (ID).
    explanation: >-
      Summarizes the allelic spectrum of GABRB3, of which this entry curates the
      encephalopathic end.

diagnosis:
- name: Trio exome/genome sequencing or epilepsy gene panel
  description: >-
    Diagnosis is molecular: identification of a heterozygous pathogenic GABRB3
    variant on a targeted epilepsy gene panel or on exome/genome sequencing,
    ideally in a proband-plus-parents (trio) design so that de novo status can be
    established. Chromosomal microarray should also be considered to exclude the
    mechanistically distinct 15q11.2-q13.1 deletion that also removes GABRB3.
  evidence:
  - reference: PMID:26645412
    reference_title: "GABRB3 mutations: a new and emerging cause of early infantile epileptic encephalopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Novel genetic technologies, such as whole-exome/genome sequencing and multiple gene panels, will undoubtedly identify further cases, allowing more detailed electroclinical delineation of the GABRB3-related genotypic and phenotypic spectra.
    explanation: >-
      Supports gene panels and exome/genome sequencing as the diagnostic route
      for GABRB3-related epileptic encephalopathy.

- name: Functional (electrophysiological) variant classification
  description: >-
    Beyond confirming a variant, determining whether it is gain-of-function or
    loss-of-function has direct therapeutic consequences, because the two classes
    respond oppositely to drugs that raise tonic GABAergic current. Classification
    is done by two-electrode voltage-clamp or patch-clamp electrophysiology of
    the variant receptor, and the variant's structural location (extracellular
    domain versus pore-lining transmembrane domain) provides partial prediction
    when functional data are unavailable.
  evidence:
  - reference: PMID:34906499
    reference_title: "Structural mapping of GABRB3 variants reveals genotype-phenotype correlations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      These genotype-phenotype correlations will aid the genetic counseling and treatment of individuals affected by GABRB3-related disorders.
    explanation: >-
      Supports using variant structural/functional classification to inform
      counselling and treatment.
  - reference: PMID:33585817
    reference_title: "Gain-of-function GABRB3 variants identified in vigabatrin-hypersensitive epileptic encephalopathies."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      This study demonstrates that functional genomics can explain beneficial and adverse anti-epileptic drug effects, and propose that vigabatrin should be considered in patients with clear loss-of-function GABRB3 variants.
    explanation: >-
      Directly ties functional classification of the variant to a drug-selection
      decision.

differential_diagnoses:
- name: Angelman syndrome (15q11.2-q13.1 deletion)
  description: >-
    Large maternal 15q11.2-q13.1 deletions remove GABRB3 together with UBE3A,
    GABRA5, GABRG3, and OCA2, and produce developmental delay, seizures, and
    hypotonia that overlap DEE43 clinically. The mechanism is different — a
    contiguous-gene deletion with UBE3A loss as the primary driver and GABRB3
    co-deletion as a severity modifier — and management and counselling differ,
    so chromosomal microarray should be used to separate the two. Ocular
    hypopigmentation, long attributed to OCA2 deletion, is at least partly a
    GABRB3 effect: deleting Gabrb3 alone causes near-complete loss of retinal
    pigmentation in mice.
  disease_term:
    preferred_term: Angelman syndrome
    term:
      id: MONDO:0007113
      label: Angelman syndrome
  evidence:
  - reference: PMID:9763493
    reference_title: "Mice lacking the beta3 subunit of the GABAA receptor have the epilepsy phenotype and many of the behavioral characteristics of Angelman syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      This study examines whether a loss or reduction in the GABAA receptor beta3 subunit (GABRB3) gene, contained within the AS deletion region, may contribute to the overall severity of AS.
    explanation: >-
      Frames GABRB3 as a gene within the Angelman deletion region contributing to
      that syndrome's severity — the basis for the clinical overlap and for
      keeping the two entities distinct.
  - reference: PMID:28009282
    reference_title: "Beyond Epilepsy and Autism: Disruption of GABRB3 Causes Ocular Hypopigmentation."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      We report here a robust phenotype in the mouse in which deletion of Gabrb3 alone causes nearly complete loss of retinal pigmentation due to atrophied melanosomes, as evidenced by electron microscopy.
    explanation: >-
      Shows that GABRB3 loss alone drives ocular hypopigmentation, refining how
      the Angelman-region pigmentary phenotype should be attributed.

- name: Childhood absence epilepsy
  description: >-
    GABRB3 has a long-standing association with childhood absence epilepsy, a
    far milder, non-encephalopathic phenotype identified through family-based
    association rather than through de novo pathogenic variants. It sits at the
    opposite end of the GABRB3 allelic spectrum from DEE43 and is deliberately
    outside this entry's scope.
  disease_term:
    preferred_term: childhood absence epilepsy
    term:
      id: MONDO:0010826
      label: childhood absence epilepsy
  evidence:
  - reference: PMID:10509183
    reference_title: "Possible association between childhood absence epilepsy and the gene encoding GABRB3."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The present data suggest that the tested polymorphism may be either directly involved in the etiology of CAE or in linkage disequilibrium with disease-predisposing sites.
    explanation: >-
      Supports a GABRB3 association with childhood absence epilepsy. Marked
      PARTIAL because the authors themselves cannot distinguish direct
      involvement from linkage disequilibrium.

- name: Lennox-Gastaut syndrome
  description: >-
    Lennox-Gastaut syndrome is an electroclinical syndrome diagnosis, not an
    alternative aetiology: a proportion of GABRB3-related DEE patients are
    labelled with it, and the two mouse knock-ins that model specific human
    GABRB3 variants (D120N, N328D) were both built to model GABRB3-associated
    Lennox-Gastaut syndrome. It is listed here because the syndromic label is
    what a patient usually carries before genetic testing, and it does not by
    itself identify the gene or predict the vigabatrin hazard, which depends on
    the variant's functional class.
  distinguishing_features:
  - >-
    The syndromic diagnosis describes seizure semiology and EEG pattern; it does
    not specify aetiology, and Lennox-Gastaut syndrome has many other genetic
    and structural causes.
  - >-
    Establishing GABRB3 as the cause requires molecular testing; the
    gain-of-function versus loss-of-function classification of the variant then
    determines whether vigabatrin is appropriate or hazardous.
  disease_term:
    preferred_term: Lennox-Gastaut syndrome
    term:
      id: MONDO:0016532
      label: Lennox-Gastaut syndrome
  evidence:
  - reference: PMID:31435640
    reference_title: "Synaptic clustering differences due to different GABRB3 mutations cause variable epilepsy syndromes."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Mutations in GABRB3 have been increasingly recognized as a major cause for severe paediatric epilepsy syndromes such as Lennox-Gastaut syndrome, Dravet syndrome and infantile spasms with intellectual disability as well as relatively mild epilepsy syndromes such as childhood absence epilepsy.
    explanation: >-
      Places Lennox-Gastaut syndrome among the syndromic presentations GABRB3
      variants produce. Evidence source is OTHER because this sentence
      summarizes the field rather than reporting the study's own data.

- name: Epilepsy of infancy with migrating focal seizures
  description: >-
    EIMFS is likewise a syndromic presentation rather than a competing
    aetiology, and within GABRB3 it is not randomly distributed: it marks the
    most severe gain-of-function subgroup, whose variants reduce receptor
    desensitization at equilibrium and which also carries the earliest seizure
    onset, movement disorder, and risk of early mortality. Three of 26 patients
    in one GABRB3 cohort were diagnosed with EIMFS.
  distinguishing_features:
  - >-
    EIMFS has many genetic causes, KCNT1 being the most common; a GABRB3 cause
    is established only by sequencing.
  - >-
    Within GABRB3, an EIMFS presentation should raise suspicion of a
    reduced-desensitization gain-of-function variant, which is precisely the
    group in which vigabatrin is hazardous.
  disease_term:
    preferred_term: epilepsy of infancy with migrating focal seizures
    term:
      id: MONDO:0017385
      label: malignant migrating partial seizures of infancy
  evidence:
  - reference: PMID:37647766
    reference_title: "Correlations of receptor desensitization of gain-of-function GABRB3 variants with clinical severity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This included younger age of first seizure onset (median 0.5 months), movement disorders (dystonia and dyskinesia), epilepsy of infancy with migrating focal seizures (EIMFS) and risk of early mortality.
    explanation: >-
      Ties the EIMFS presentation to the reduced-desensitization gain-of-function
      subgroup rather than to GABRB3 disease generally.
  - reference: PMID:34698933
    reference_title: "GABRB3-related epilepsy: novel variants, clinical features and therapeutic implications."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Eleven patients were diagnosed with developmental and epileptic encephalopathy (DEE), four with West syndrome, three with epilepsy of infancy with migrating focal seizures (EIMFS), one with epilepsy with myoclonic-atonic seizures (EMAS), one with Dravet syndrome, and one with febrile seizures plus (FS+).
    explanation: >-
      Quantifies EIMFS as 3 of 26 patients in a GABRB3 cohort.

treatments:
- name: Broad-spectrum antiseizure medication (valproate, levetiracetam, perampanel)
  description: >-
    Conventional antiseizure medications remain the mainstay, usually as
    polytherapy. In a 26-patient cohort, seizures were controlled in 57.7% of
    patients, most often with valproate, levetiracetam, or perampanel, so
    drug-resistance is common but far from universal.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: valproic acid
      term:
        id: CHEBI:39867
        label: valproic acid
    - preferred_term: levetiracetam
      term:
        id: CHEBI:6437
        label: levetiracetam
    - preferred_term: perampanel
      term:
        id: CHEBI:71013
        label: perampanel
  target_mechanisms:
  - target: Neuronal Hyperexcitability and Thalamocortical Hypersynchrony
    treatment_effect: INHIBITS
    description: >-
      These agents act downstream of the receptor lesion, suppressing network
      hyperexcitability rather than correcting the GABA-A receptor defect.
    evidence:
    - reference: PMID:34698933
      reference_title: "GABRB3-related epilepsy: novel variants, clinical features and therapeutic implications."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Seizures were controlled in 57.7% of patients by valproate, levetiracetam, or perampanel in the majority.
      explanation: >-
        Shows these agents suppress the seizure output of the hyperexcitable
        network in a majority of the patients who achieved control, without
        addressing the receptor lesion itself.
  evidence:
  - reference: PMID:34698933
    reference_title: "GABRB3-related epilepsy: novel variants, clinical features and therapeutic implications."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Seizures were controlled in 57.7% of patients by valproate, levetiracetam, or perampanel in the majority.
    explanation: >-
      Directly reports the agents most often associated with seizure control and
      the proportion of patients controlled.
  - reference: PMID:34698933
    reference_title: "GABRB3-related epilepsy: novel variants, clinical features and therapeutic implications."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Valproate, levetiracetam and perampanel seem to have positive effects on seizure control for patients with GABRB3 variants.
    explanation: >-
      The authors' own summary of which agents appear effective in GABRB3-related
      epilepsy.

- name: Vigabatrin (variant-class dependent — contraindicated in gain-of-function)
  description: >-
    Vigabatrin inhibits GABA transaminase and thereby raises tonic GABAergic
    current. Its effect in GABRB3-related DEE depends on which functional class
    the variant belongs to, and getting this wrong is harmful rather than merely
    ineffective. In loss-of-function variants it is expected to be safe and
    effective and a truncating-variant patient responded well. In
    gain-of-function variants it produces a hypersensitivity reaction with
    hypotonia, sedation, and respiratory suppression, because it further
    exaggerates an already excessive tonic current. Functional or structural
    classification of the variant should therefore precede a vigabatrin trial.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: vigabatrin
      term:
        id: CHEBI:63638
        label: vigabatrin
  target_mechanisms:
  - target: Loss-of-Function Reduction in GABA-A Receptor Function
    treatment_effect: RESTORES
    description: >-
      By raising ambient GABA, vigabatrin compensates for reduced GABA-gated
      current in loss-of-function variants. The same action is the reason it is
      hazardous in gain-of-function variants.
    evidence:
    - reference: PMID:33585817
      reference_title: "Gain-of-function GABRB3 variants identified in vigabatrin-hypersensitive epileptic encephalopathies."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        In contrast, drug strategies increasing tonic currents in loss-of-function variants are likely to be a safe and effective therapy.
      explanation: >-
        States that raising tonic current is the appropriate corrective strategy
        specifically for loss-of-function variants. Evidence source is OTHER
        because this is the authors' therapeutic recommendation inferred from
        their electrophysiology, not a measured clinical or in vitro result.
  evidence:
  - reference: PMID:33585817
    reference_title: "Gain-of-function GABRB3 variants identified in vigabatrin-hypersensitive epileptic encephalopathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      However, vigabatrin, a drug that inhibits γ-aminobutyric acid transaminase to increase tonic γ-aminobutyric acid currents, has mixed success in treating seizures in patients with GABRB3 variants: some patients experience seizure cessation, but there is hypersensitivity in some patients associated with hypotonia, sedation and respiratory suppression.
    explanation: >-
      Documents both the benefit and the specific adverse reaction — hypotonia,
      sedation, respiratory suppression — that make vigabatrin variant-class
      dependent.
  - reference: PMID:33585817
    reference_title: "Gain-of-function GABRB3 variants identified in vigabatrin-hypersensitive epileptic encephalopathies."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      We therefore propose that the hypersensitivity reaction to vigabatrin is a result of GABRB3 variants that exacerbate GABAergic tonic currents and caution is required when prescribing vigabatrin.
    explanation: >-
      Gives the mechanistic reason for the contraindication in gain-of-function
      variants and the explicit prescribing caution.

- name: Benzodiazepines (nitrazepam, clonazepam)
  description: >-
    Benzodiazepines are also GABA-potentiating, but they act predominantly on
    phasic synaptic currents rather than the tonic extrasynaptic currents that
    vigabatrin raises — which is the mechanistic reason they were tolerated by a
    gain-of-function patient who could not tolerate vigabatrin. A patient with
    the gain-of-function p.Glu77Lys variant stabilized on nitrazepam plus the
    ketogenic diet, and a separate case report describes complete seizure
    cessation on clonazepam.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: nitrazepam
      term:
        id: CHEBI:7581
        label: nitrazepam
    - preferred_term: clonazepam
      term:
        id: CHEBI:3756
        label: clonazepam
  target_mechanisms:
  - target: Disrupted Excitation-Inhibition Balance in Developing Networks
    treatment_effect: MODULATES
    description: >-
      Positive allosteric modulation of synaptic GABA-A receptors prolongs
      inhibitory postsynaptic currents, acting on the phasic rather than the
      tonic compartment.
    evidence:
    - reference: PMID:33585817
      reference_title: "Gain-of-function GABRB3 variants identified in vigabatrin-hypersensitive epileptic encephalopathies."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        Benzodiazepines, including nitrazepam, are positive allosteric modulators of GABAA receptors that predominately affect phasic currents, usually through prolonging inhibitory postsynaptic currents
      explanation: >-
        Specifies the compartment (phasic, not tonic) in which benzodiazepines
        modulate inhibitory signalling, which is why they act on this node
        without the vigabatrin hazard.
  evidence:
  - reference: PMID:33585817
    reference_title: "Gain-of-function GABRB3 variants identified in vigabatrin-hypersensitive epileptic encephalopathies."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Benzodiazepines, including nitrazepam, are positive allosteric modulators of GABAA receptors that predominately affect phasic currents, usually through prolonging inhibitory postsynaptic currents
    explanation: >-
      Gives the pharmacological basis for why benzodiazepines behave differently
      from vigabatrin in gain-of-function patients.
  - reference: PMID:33585817
    reference_title: "Gain-of-function GABRB3 variants identified in vigabatrin-hypersensitive epileptic encephalopathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      She was subsequently stabilized and spasms ceased on a combination of nitrazepam and the ketogenic diet.
    explanation: >-
      Documents clinical stabilization on nitrazepam plus ketogenic diet in a
      vigabatrin-hypersensitive gain-of-function patient.
  - reference: PMID:29390378
    reference_title: "Early onset epileptic encephalopathy with a novel GABRB3 mutation treated effectively with clonazepam: A case report."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Our finding suggested that clonazepam might be a choice for patient with GABRB3-related EOEE.
    explanation: >-
      Single-case evidence that clonazepam can control seizures in
      GABRB3-related early-onset epileptic encephalopathy.

- name: Ketogenic diet
  description: >-
    The ketogenic diet is used as an adjunct in refractory GABRB3-related
    epilepsy; it contributed to seizure cessation in combination with nitrazepam
    in a vigabatrin-hypersensitive gain-of-function patient.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: ketogenic diet
    term:
      id: NCIT:C15447
      label: Dietary Intervention
  evidence:
  - reference: PMID:33585817
    reference_title: "Gain-of-function GABRB3 variants identified in vigabatrin-hypersensitive epileptic encephalopathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      She was subsequently stabilized and spasms ceased on a combination of nitrazepam and the ketogenic diet.
    explanation: >-
      Supports adjunctive use of the ketogenic diet. Marked PARTIAL because the
      diet was given with nitrazepam in a single patient, so its independent
      contribution cannot be separated.

- name: Cannabidiol (preclinical)
  description: >-
    Cannabidiol reduced both atypical absence seizures and epileptic spasms in
    the Gabrb3 D120N knock-in mouse, which models a human Lennox-Gastaut-phenotype
    GABRB3 variant. This is a mouse-model result in a single modelled variant and
    has not been tested clinically in GABRB3-related DEE, so it is recorded as a
    preclinical rationale rather than as an established therapy.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: cannabidiol
      term:
        id: CHEBI:69478
        label: cannabidiol
  evidence:
  - reference: PMID:42274296
    reference_title: "Cannabidiol reduces atypical absence seizures and epileptic spasms in a Gabrb3(+/D120N) mouse model of Lennox-Gastaut syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      CBD and vigabatrin significantly reduced spasm frequency compared to the vehicle.
    explanation: >-
      Reports cannabidiol efficacy against epileptic spasms in the Gabrb3 D120N
      knock-in mouse. Evidence source is MODEL_ORGANISM; this has not been shown
      in patients.
  - reference: PMID:32467926
    reference_title: "GABA(A) receptor β3 subunit mutation D120N causes Lennox-Gastaut syndrome in knock-in mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      In addition, treatment with antiepileptic drugs and cannabinoids ameliorated atypical absence seizures in knock-in mice.
    explanation: >-
      Independent mouse-model evidence that cannabinoids reduce atypical absence
      seizures in the same knock-in line.

animal_models:
- species: Mus musculus
  genotype: Gabrb3+/D120N knock-in
  description: >-
    Heterozygous knock-in of the human de novo p.D120N Lennox-Gastaut variant.
    The model reproduces the human syndrome's seizure repertoire and behavioural
    profile and localizes the defect to inhibitory signalling in the
    thalamocortical loop, making it the closest available in vivo proxy for a
    specific human GABRB3 genotype.
  genes:
  - preferred_term: GABRB3
    term:
      id: hgnc:4083
      label: GABRB3
  evidence:
  - reference: PMID:32467926
    reference_title: "GABA(A) receptor β3 subunit mutation D120N causes Lennox-Gastaut syndrome in knock-in mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      we generated the heterozygous Gabrb3+/D120N knock-in mouse and found that it had frequent spontaneous atypical absence seizures, as well as less frequent tonic, myoclonic, atonic and generalized tonic-clonic seizures.
    explanation: >-
      Describes the model and its multi-seizure-type phenotype.

- species: Mus musculus
  genotype: Gabrb3+/N328D knock-in
  description: >-
    Heterozygous knock-in of the human p.N328D Lennox-Gastaut variant, with
    spontaneous seizures, cognitive impairment, and reduced beta-3 subunit
    expression in cerebellum, hippocampus, and thalamus.
  genes:
  - preferred_term: GABRB3
    term:
      id: hgnc:4083
      label: GABRB3
  evidence:
  - reference: PMID:37176165
    reference_title: "GABA(A) Receptor β3 Subunit Mutation N328D Heterozygous Knock-in Mice Have Lennox-Gastaut Syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Gabrb3+/N328D mice showed spontaneous seizures and signs of cognitive impairment, including deficits in spatial learning, memory, and locomotion.
    explanation: >-
      Documents the seizure and cognitive phenotype of the second knock-in model.

- species: Mus musculus
  genotype: Gabrb3 null (knockout)
  description: >-
    Constitutive Gabrb3 knockout. Halved brain GABA-A receptor density, severely
    impaired receptor function, myoclonus and epileptic seizures on EEG, high
    neonatal mortality with cleft palate, and an Angelman-like behavioural
    profile. It models the loss-of-function extreme rather than the human
    gain-of-function spectrum.
  genes:
  - preferred_term: GABRB3
    term:
      id: hgnc:4083
      label: GABRB3
  evidence:
  - reference: PMID:9108119
    reference_title: "Mice devoid of gamma-aminobutyrate type A receptor beta3 subunit have epilepsy, cleft palate, and hypersensitive behavior."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      beta3-deficient mice display frequent myoclonus and occasional epileptic seizures, documented by electroencephalographic recording.
    explanation: >-
      Documents the seizure phenotype of the constitutive knockout.
  - reference: PMID:9763493
    reference_title: "Mice lacking the beta3 subunit of the GABAA receptor have the epilepsy phenotype and many of the behavioral characteristics of Angelman syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Additionally, these mice exhibited learning and memory deficits, poor motor skills on a repetitive task, hyperactivity, and a disturbed rest-activity cycle, features all common to AS.
    explanation: >-
      Documents the behavioural phenotype of the knockout and its Angelman
      syndrome resemblance.

datasets: []

discussions:
- discussion_id: controversy_gabrb3_gof_paradox
  prompt: >-
    Why do gain-of-function GABRB3 variants — which increase the potency of an
    inhibitory neurotransmitter receptor — produce an earlier-onset and more
    severe epileptic encephalopathy than loss-of-function variants?
  kind: CONTROVERSY
  status: OPEN
  attaches_to:
  - pathophysiology#Gain-of-Function Increase in GABA Sensitivity
  - pathophysiology#Disrupted Excitation-Inhibition Balance in Developing Networks
  rationale: >-
    The excitation-inhibition framework predicts that reduced GABAergic
    inhibition causes seizures, and GABA-A receptor epilepsy variants were
    presumed to act that way. GABRB3 breaks the prediction: the class of variants
    that increases GABAergic activity has the worse outcome. Candidate
    explanations include preferential amplification of tonic extrasynaptic
    current, depolarizing GABA responses in immature neurons with high
    intracellular chloride, and disruption of the developmental patterning role
    of GABAergic signalling — but these have not been discriminated
    experimentally, and the answer determines whether GABA-enhancing drugs help
    or harm a given patient.
  evidence:
  - reference: PMID:35383156
    reference_title: "Gain-of-function and loss-of-function GABRB3 variants lead to distinct clinical phenotypes in patients with developmental and epileptic encephalopathies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Overall, patients with GABRB3 variants that increase GABAergic activity have more severe developmental and epileptic encephalopathies. This paradoxical finding challenges our current understanding of the GABAergic system in epilepsy and how patients should be treated.
    explanation: >-
      States the paradox and its unresolved status in the authors' own words.

- discussion_id: mismatch_gabrb3_mouse_models_lof_only
  prompt: >-
    Do the available Gabrb3 mouse models represent the human gain-of-function
    arm of DEE43, or only its loss-of-function arm — and can drug-response
    findings from them (notably cannabidiol) be generalized across the two
    functional classes?
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  attaches_to:
  - pathophysiology#Gain-of-Function Increase in GABA Sensitivity
  rationale: >-
    Every in vivo Gabrb3 model in current use sits on one side of the human
    disease. The constitutive knockout removes the subunit entirely, which is a
    loss-of-function extreme and additionally produces an Angelman-like
    phenotype rather than DEE43. The two knock-in lines (D120N, N328D) each model
    a single Lennox-Gastaut-associated human variant. No published model
    reproduces the reduced-desensitization gain-of-function subgroup that carries
    the earliest onset, movement disorder, and early-mortality risk in patients.
    This matters concretely: cannabidiol efficacy has been shown in the D120N
    line and is being read as a rationale for human use, but the functional class
    of D120N cannot be assumed to represent the gain-of-function patients in whom
    GABA-directed drugs behave oppositely.
  evidence:
  - reference: PMID:9763493
    reference_title: "Mice lacking the beta3 subunit of the GABAA receptor have the epilepsy phenotype and many of the behavioral characteristics of Angelman syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      The loss of the single gene, gabrb3, in these mice is sufficient to cause phenotypic traits that have marked similarities to the clinical features of AS, indicating that impaired expression of the GABRB3 gene in humans probably contributes to the overall phenotype of Angelman syndrome.
    explanation: >-
      Shows the knockout is framed and validated as an Angelman syndrome model,
      not as a model of the human GABRB3 DEE gain-of-function spectrum.
  - reference: PMID:42274296
    reference_title: "Cannabidiol reduces atypical absence seizures and epileptic spasms in a Gabrb3(+/D120N) mouse model of Lennox-Gastaut syndrome."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Gabrb3+/D120N mice display robust atypical absence seizures and neonatal spasms that respond to antiseizure agents, supporting the predictive validity of this model as a preclinical platform for LGS drug discovery.
    explanation: >-
      States the predictive-validity claim that this mismatch discussion asks to
      be tested across functional classes rather than assumed.

notes: >-
  Scope. This entry curates DEE43, the encephalopathic end of the GABRB3 allelic
  spectrum, anchored on MONDO:0014921. GABRB3's milder associations (childhood
  absence epilepsy, febrile seizures) and its role as a co-deleted severity
  modifier in Angelman syndrome are recorded as differentials rather than as
  subtypes, because those are separate disease entities with different
  mechanisms, not gradations of this one.

  Frequency provenance and its scope limit. The percentage-backed frequency
  bands come from published GABRB3-related-epilepsy cohorts, not from
  DEE43-restricted series. The 26-patient Yang cohort supplying most of them
  (focal seizures 92.3%, developmental delay 96.2%, fever sensitivity 53.8%,
  generalized tonic-clonic 23.1%, epileptic spasms 15.4%) is predominantly but
  not exclusively encephalopathic: it also contains one febrile-seizures-plus,
  one Dravet, and one myoclonic-atonic case. The bands should therefore be read
  as applying to GABRB3-related epilepsy broadly, and as close to but not
  identical with the DEE43 subset this entry is scoped to. A DEE43-restricted
  frequency set would need a cohort that has not yet been published.

  Curation provenance. Built from a claude_code deep-research report
  (research/GABRB3-Related_Developmental_and_Epileptic_Encephalopathy-deep-research-claude_code.md).
  Three errors in that report were caught and corrected during curation and are
  recorded here so they are not reintroduced: it gave GABRB3 as HGNC:4082 (that
  is GABRB2; the correct identifier is hgnc:4083), and it proposed HP:0032500
  for migrating focal seizures and HP:0002518 for Lennox-Gastaut syndrome, both
  of which are unrelated HPO terms (Exacerbated by tobacco use, and Abnormal
  periventricular white matter morphology respectively). Every ontology term in
  this entry was verified against OAK.

  Not curated for lack of citable evidence. Cluster seizures (80.8% in the Yang
  cohort) have no suitable HPO term and are described in prose instead. A
  ClinGen gene-disease validity assertion could not be cited because the pinned
  ClinGen gene_validity.csv checksum in data/clingen/MANIFEST.yaml no longer
  matches the upstream file, so `just clingen-refresh` fails; that is a
  repository maintenance issue independent of this entry.

  Datasets. `just discover-datasets` returned 12 candidates, all tagged DIRECT,
  and none of them is about GABRB3: they cover GLUL, CDKL5, SCN1A/Dravet, SCN8A,
  and PNPLA8 disease models and were surfaced by a text match on the phrase
  "developmental epileptic encephalopathy" in the entry name. That is the Named
  Entity Confusion pattern the curation SOP warns about reached through dataset
  search, so `datasets` is deliberately left empty rather than populated with
  accessions that resolve but describe a different disease. A GABRB3-specific
  omics dataset should be added if one is published; the receptor is studied
  almost entirely by targeted electrophysiology rather than by unbiased omics,
  so none may exist yet.

📚

References & Deep Research

References

5

PMID:35383156

Gain-of-function and loss-of-function GABRB3 variants lead to distinct clinical phenotypes in patients with developmental and epileptic encephalopathies.

No top-level findings curated for this source.

PMID:34906499

Structural mapping of GABRB3 variants reveals genotype-phenotype correlations.

No top-level findings curated for this source.

PMID:34698933

GABRB3-related epilepsy: novel variants, clinical features and therapeutic implications.

No top-level findings curated for this source.

PMID:33585817

Gain-of-function GABRB3 variants identified in vigabatrin-hypersensitive epileptic encephalopathies.

No top-level findings curated for this source.

PMID:37647766

Correlations of receptor desensitization of gain-of-function GABRB3 variants with clinical severity.

No top-level findings curated for this source.

Deep Research

1

Claude Code ▸

GABRB3-Related Developmental and Epileptic Encephalopathy: Comprehensive Research Report

claude-haiku-4-5-20251001, claude-sonnet-5 1 citations 2026-08-08T22:09:13.232521

GABRB3-Related Developmental and Epileptic Encephalopathy: Comprehensive Research Report

1. Disease Information

Overview. GABRB3-Related Developmental and Epileptic Encephalopathy — catalogued in OMIM as Developmental and Epileptic Encephalopathy 43 (DEE43) — is an autosomal dominant neurodevelopmental disorder caused by heterozygous, almost always de novo, pathogenic variants in GABRB3, the gene encoding the β3 subunit of the GABA_A receptor. It presents with onset of diverse, typically treatment-refractory seizure types in infancy (median onset in the first year of life, commonly 2–10 months), accompanied by global developmental delay and mild-to-profound intellectual disability. It sits within a broader phenotypic continuum: the same gene, at the mild end, causes childhood absence epilepsy and febrile seizures, and at the severe end causes early infantile DEE/epilepsy of infancy with migrating focal seizures (EIMFS)-like presentations, West syndrome (infantile spasms), and Lennox-Gastaut syndrome (LGS) (PMID:26645412; PMID:35383156; PMID:34698933).

Key identifiers: - OMIM gene: 137192 (GABRB3) — https://omim.org/entry/137192 - OMIM phenotype: #617113 — Developmental and Epileptic Encephalopathy 43 (DEE43) - HGNC gene symbol: GABRB3 (NCBI Gene ID 2562); cytogenetic location 15q12 (GRCh38: chr15:26,543,552–26,773,763) - MONDO: DEE43 maps to a MONDO term for GABRB3-related DEE (verify exact CURIE via OAK before curating — not independently confirmed in this research pass) - Orphanet: GABRB3 is a listed causal gene in Orphanet's gene-disease association tables (Orphanet gene search interface referenced above) - Inheritance/molecular basis:* Autosomal dominant, heterozygous, predominantly de novo missense (occasionally nonsense/truncating) variants

Synonyms/alternative names: DEE43; GABRB3-related epilepsy; GABRB3 encephalopathy; (historically, before the DEE nomenclature consolidation) "early infantile epileptic encephalopathy due to GABRB3 mutation"; GABRB3 is also implicated (as a distinct, milder end of spectrum, not to be conflated with DEE43 itself) in childhood absence epilepsy (CAE) and, via contiguous-gene deletion of 15q11.2-q13.1, in Angelman syndrome/Prader-Willi syndrome region phenotypes.

Evidence basis. Almost all published information is aggregated, multicenter, disease-level cohort data (case series pooling tens of patients across specialized epilepsy genetics centers, e.g., the Nature Communications 2022 cohort of 74 patients and the Journal of Neurology 2022 cohort of 26 patients) rather than large-scale EHR/registry data — this is a rare, molecularly defined disorder without a dedicated patient registry captured in the literature reviewed here.

2. Etiology

Disease causal factor: Purely monogenic/genetic. Heterozygous, predominantly de novo, missense (rarely nonsense, frameshift, or small in-frame indel) variants in GABRB3 are both necessary and sufficient to cause DEE43; there is no known environmental, infectious, or purely mechanistic non-genetic cause.

Genetic risk factors: - De novo status: In the largest cohorts, the overwhelming majority of pathogenic variants arise de novo (e.g., 25 of 26 variants in the Yang et al. 2022 Chinese multicenter cohort were de novo; PMID:34698933). Inherited transmission from an affected or mosaic parent is rare but documented. - Parental mosaicism: Because the majority of variants are de novo, apparently unaffected parents can nonetheless harbor low-level somatic/gonadal mosaicism; amplicon-based deep sequencing studies of DEE cohorts broadly (not GABRB3-specific) find mosaicism in roughly 10–12% of "de novo" epilepsy cases, with recurrence risk to siblings ranging from the general de novo empiric range of 1–5% up to ~50% when robust parental gonadal mosaicism is confirmed (general DEE mosaicism literature, not GABRB3-specific — apply with appropriate caveat). - Locus/domain of the variant functions as a structural risk/severity modifier (see Genetics section) rather than a distinct risk factor per se. - Chromosomal (contiguous-gene) risk: GABRB3 lies within the 15q11.2-q13.1 Prader-Willi/Angelman syndrome (PWS/AS) critical region, ~100 kb telomeric of GABRA5 and in a cluster with GABRG3. Large maternal deletions of this region spanning UBE3A through GABRB3 (Class I/II AS deletions, ~5–7 Mb) produce a more severe Angelman syndrome phenotype with higher seizure burden than deletions or point mutations restricted to UBE3A alone — implicating GABRB3 haploinsufficiency as a phenotype-modifying, but not independently disease-defining, contiguous-gene factor in that separate disorder.

Protective factors: None specifically documented for GABRB3-related DEE in the literature surveyed. No protective alleles or environmental protective factors are reported.

Gene-environment interactions: Not reported as a feature of this monogenic disorder. The principal environment-like modifier is iatrogenic: pharmacologic exposure (notably vigabatrin) interacts with the functional class of the underlying variant to produce divergent, variant-specific drug responses (see Treatment, below) — a gene-drug rather than gene-environment interaction.

3. Phenotypes

Core seizure phenotypes (symptoms/signs, HPO-mappable)

Multiple, usually pharmacoresistant seizure types typically emerge in the first year of life: - Febrile seizures (HP:0002373) — onset feature almost exclusively in the loss-of-function cohort (PMID:35383156) - Focal seizures (HP:0007359 or HP:0011169 focal-onset seizure) — reported in up to 92.3% of a 26-patient cohort (PMID:34698933) - Infantile spasms / epileptic spasms (HP:0011097) — 15.4%–substantial minority; frequently evolving to West syndrome - Generalized tonic-clonic seizures (HP:0002069) — ~23.1% - Myoclonic seizures (HP:0032789 / HP:0002123) - Atypical absence seizures (HP:0007270) and atonic seizures (HP:0010819) — prominent in Lennox-Gastaut-associated variants - Cluster seizures (non-HPO-specific clinical descriptor) — 80.8% of the Yang 2022 cohort - Fever sensitivity/exacerbation — 53.8% - Evolution to Lennox-Gastaut syndrome (HP:0002518) or, at the severe extreme, epilepsy of infancy with migrating focal seizures (EIMFS) (HP:0032500)

Developmental/cognitive phenotypes

Global developmental delay (HP:0001263) — reported in ~96.2% of cohort patients
Intellectual disability, ranging mild to profound (HP:0001249, or graded HP:0001256 mild / HP:0002342 moderate / HP:0010864 severe / HP:0006889 profound), correlating with variant functional class and structural domain
Hypotonia (HP:0001252) — common, especially neonatal presentation, and a hallmark of gain-of-function variants
Motor disability / non-ambulation in severe cases
Absent or limited speech (HP:0001344 / HP:0002465) in severely affected individuals
Autistic features / autism spectrum disorder (HP:0000717) — GABRB3 is an established SFARI-listed autism candidate gene independent of the DEE43 phenotype (see Genetic/Molecular section)

Movement disorder phenotypes (severe end of spectrum)

Dystonia (HP:0001332) and dyskinesia (HP:0100660) — associated specifically with gain-of-function variants that show reduced/altered receptor desensitization, and with earlier age of first seizure (median 0.5 months) and risk of early mortality (PMID:37647766)

Ophthalmologic phenotype

Ocular hypopigmentation — an unusual, specifically reported extra-neurologic phenotype (mouse-model-confirmed, with human correlate reported) reflecting a role for GABRB3 beyond CNS inhibition (PMID:28009282); candidate HPO term: HP:0007894 (Iris hypopigmentation) or broader ocular pigmentation abnormality term — verify exact term via OAK.

Neuroimaging (structural) phenotypes

MRI is frequently normal, but when abnormal has shown: polymicrogyria (HP:0002126), diffuse hypomyelination (HP:0008268), cerebellar hypoplasia (HP:0001321), cortical/brainstem atrophy, and bifrontal heterotopia (HP:0002282) in isolated case reports — notably with incomplete penetrance of the imaging finding even among carriers of the identical variant (e.g., two patients with the same de novo p.R232Q variant, one with heterotopia and one with unremarkable MRI), underscoring marked phenotypic variability beyond genotype alone.

Characteristics

Age of onset: neonatal period to ~12 months typically; median onset figures reported range from 0.5 months (severe gain-of-function, reduced-desensitization variants) to 3.75–10.5 months depending on cohort and variant functional class (PMID:34698933; PMID:34906499; PMID:37647766)
Severity/progression: Highly variable — from relatively mild childhood absence epilepsy at one extreme to profound DEE, movement disorder, and early mortality at the other, tracking closely with variant functional class and structural location
Frequency: All figures above are qualitative/cohort-derived percentages from small multicenter case series (n=26–74), not general-population prevalence estimates
Quality of life impact: Not separately quantified in the literature surveyed (no EQ-5D/SF-36/disease-specific QOL instrument data identified for GABRB3-DEE specifically); qualitatively, severe motor and cognitive impairment plus refractory seizures impose substantial caregiver burden and reduced functional independence, consistent with DEE literature broadly.

4. Genetic/Molecular Information

Causal gene: GABRB3 (HGNC:4082; NCBI Gene 2562; OMIM 137192), encoding the GABA_A receptor β3 subunit, located at 15q12, spanning ~230 kb, transcribed in the opposite orientation from its neighbors GABRA5 and GABRG3* within the same 15q11-q13 gene cluster.

Variant landscape: - Predominantly missense variants; occasional nonsense/truncating and small in-frame indel variants - As of the 2022 Nature Communications synthesis, 44 distinct pathogenic GABRB3 missense variants had been characterized functionally and clinically, cohorted into 27 gain-of-function (GOF) and 47 loss-of-function (LOF) patients (PMID:35383156) - ClinVar contains multiple GABRB3 variant/DEE43 records (e.g., NM_000814.6(GABRB3):c.1052A>G / p.Asn351Ser, classified pathogenic for DEE43) - Nearly all reported variants are de novo (~96% in the largest single-cohort report)

Functional classification — the central genotype-phenotype axis: GABRB3 pathogenic variants sort into two functionally and clinically distinguishable classes (PMID:35383156; PMID:37647766; PMID:33585817): - Gain-of-function (GOF): increase GABA potency/receptor sensitivity (lower EC50) without necessarily changing maximal open probability; associated with younger age of seizure onset, higher risk of severe intellectual disability, focal seizures at onset, hypotonia, and lower likelihood of achieving seizure freedom. A further refinement (Brain, 2024; PMID:37647766) shows GOF variants that additionally reduce receptor desensitization produce the most severe subgroup — earliest onset (median 0.5 months), movement disorder (dystonia/dyskinesia), EIMFS-like presentation, and risk of early mortality; GOF variants that instead accelerate desensitization kinetics produce a comparatively milder GOF subgroup (later onset, median 4 months; unclassifiable DEE or LGS; no movement disorder). - Loss-of-function (LOF): reduced GABA_A receptor function/GABAergic disinhibition, often via impaired subunit trafficking/synaptic clustering; associated with febrile seizures at onset (a feature exclusive to this group) and comparatively better treatment response.

Structural mapping (Genetics in Medicine, 2021; PMID:34906499): In a cohort of 71 individuals, missense variants mapped onto the 3D GABRB3 subunit structure showed domain-specific phenotype correlation: - Extracellular domain variants → generalized epilepsy (median onset ~10.5 months) with mild-to-moderate intellectual disability - Pore-lining transmembrane (M2) domain variants → focal epilepsy with early onset (median ~2.75 months) and severe intellectual disability - Variants at the coupling junction (linking the extracellular ligand-binding domain to the transmembrane pore, e.g., loop 2/Cys-loop/M2-M3 loop) are mechanistically implicated in early-onset EE across multiple GABRB studies (PMID for Scientific Reports 2017 coupling-junction/pore paper, DOI:10.1038/s41598-017-16010-3), and structural variants across the GABRB gene family (GABRB1/2/3) converge on shared gating and trafficking defects (PMC10741827).

Modifier genes: None specifically established for GABRB3-DEE43 itself. Within the separate contiguous-gene-deletion context (Angelman syndrome), co-deletion of GABRB3 (with GABRA5, GABRG3) modifies (worsens) seizure severity relative to isolated UBE3A loss-of-function.

Chromosomal abnormalities: DEE43 as classically defined is a single-gene (missense/point-variant) disorder, distinct from the large 15q11.2-q13.1 contiguous-gene deletions that cause Angelman syndrome (which also remove GABRB3 along with UBE3A, OCA2, GABRA5, GABRG3). Do not conflate the two mechanisms when curating — Angelman syndrome deletions are a different disease entity (with GABRB3 co-deletion as a severity modifier), not DEE43 itself.

Epigenetics: No GABRB3-DEE43-specific DNA methylation/histone modification data identified in this pass; note that GABRB3 itself sits near, but is not subject to, the parent-of-origin imprinting that governs UBE3A/SNRPN in the Angelman/Prader-Willi region (GABRB3 is biallelically expressed, non-imprinted).

Suggested ontology terms: HGNC:4082 (GABRB3); GO:1902710 (GABA-A receptor complex, cellular component); GO:0004890 (GABA-A receptor activity, molecular function); GO:0007214 (gamma-aminobutyric acid signaling pathway, biological process); GO:0060080 (regulation of inhibitory postsynaptic potential).

5. Environmental Information

No environmental, lifestyle, or infectious causal or risk factors are documented for GABRB3-related DEE43 — it is a purely monogenic disorder. The one clinically important "environmental" interaction is pharmacologic (a treatment exposure, addressed under Treatment): vigabatrin exposure interacts with the underlying variant's functional class to produce divergent — sometimes harmful — clinical responses.

6. Mechanism / Pathophysiology

Causal chain overview: 1. Trigger: Heterozygous de novo missense variant in GABRB3, altering the β3 subunit of the GABA_A receptor. 2. Molecular consequence: Altered receptor pharmacology and/or biogenesis — depending on variant location and class, this manifests as (a) increased GABA potency/reduced desensitization (GOF), (b) reduced channel function or impaired subunit folding/trafficking/synaptic clustering (LOF), or (c) dominant-negative effects on heteropentameric receptor assembly (α1β3γ2 and α5β3γ2 being the principal native assemblies). 3. Cellular consequence: Altered inhibitory postsynaptic current (phasic, synaptic GABA_A signaling) and/or tonic (extrasynaptic α5β3γ2-mediated) inhibitory current in cortical/hippocampal GABAergic circuits, producing either excessive (GOF, paradoxically pro-epileptic at the network level) or insufficient (LOF) fast inhibitory neurotransmission. 4. Circuit/network consequence: Disrupted excitation-inhibition balance in developing cortical and thalamocortical networks → neuronal hyperexcitability and hypersynchrony. 5. Clinical manifestation: Multiple seizure types, developmental encephalopathy, and (in severe GOF cases) movement disorder.

A key, counterintuitive mechanistic finding: Both GOF and LOF perturbations of the same receptor subunit cause epileptic encephalopathy — and GOF variants (i.e., variants that increase GABAergic receptor function/potency) paradoxically cause the more severe phenotypes. This directly informs (and complicates) rational pharmacotherapy, since drugs that further potentiate GABAergic tone (e.g., vigabatrin) can be beneficial in LOF patients but harmful in GOF patients (PMID:35383156; PMID:33585817).

Molecular pathway/GO terms: - GO:0007214 (gamma-aminobutyric acid signaling pathway) - GO:0034220 (monoatomic ion transmembrane transport) / GO:1902476 (chloride transmembrane transport) - GO:0060080 (regulation of inhibitory postsynaptic membrane potential) - GO:0050806 (positive regulation of synaptic transmission) / GO:0051932 (synaptic transmission, GABAergic)

Cellular processes: Altered receptor trafficking to the plasma membrane and synaptic clustering (gephyrin-dependent postsynaptic scaffolding of GABA_A receptors is implicated as a shared LOF mechanism across multiple GABRB3 variants — PMID:31435640 "Synaptic clustering differences due to different GABRB3 mutations cause variable epilepsy syndromes"); altered receptor gating kinetics (open probability, desensitization) for GOF variants.

Protein structure/dysfunction: GABA_A receptors are pentameric ligand-gated chloride channels of the Cys-loop receptor superfamily; the most abundant native brain assembly relevant here is α1β3γ2 (with α5β3γ2 mediating tonic/extrasynaptic inhibition). Cryo-EM structures of the human α1β3γ2 GABA_A receptor (PDB 6HUP; Nature 2018) resolve the extracellular ligand-binding domain, the coupling/Cys-loop and M2-M3 loop "gating junction," and the M2 pore-lining transmembrane helix — the three structural zones onto which pathogenic GABRB3 variants map with distinct phenotypic consequences (extracellular domain → milder generalized epilepsy; pore-lining M2 → severe early-onset focal epilepsy; coupling junction → early-onset EE via gating/trafficking defects) (PMID:34906499; PMC10741827).

Cell types and anatomical involvement: Primarily inhibitory GABAergic interneurons and their postsynaptic targets (excitatory pyramidal/principal neurons) across cerebral cortex, hippocampus, thalamus, and cerebellum. Suggested Cell Ontology terms: CL:0000617 (GABAergic neuron), CL:0000598 (pyramidal neuron), CL:0001031 (cerebellar granule cell, relevant given cerebellar vermal hypoplasia in Gabrb3-null mice).

Immune system involvement: Not implicated; this is a primary neuronal ion-channel/synaptic disorder, not an immune/inflammatory one.

Tissue damage mechanisms: Not classically necrotic/fibrotic/ischemic — the principal "damage" is functional (network hyperexcitability, developmental miswiring) rather than structural cell death, although secondary/chronic epileptic-encephalopathy-associated cortical injury from recurrent severe seizures is plausible but not specifically documented for this gene.

Biochemical abnormality: Altered GABA_A receptor chloride channel gating/pharmacology (EC50, open probability, desensitization kinetics) as directly measured by two-electrode voltage clamp and patch-clamp electrophysiology in heterologous expression systems (e.g., Xenopus oocytes, HEK293 cells) for numerous individual variants (PMID:33585817; PMID:37647766).

Molecular/omics profiling: No transcriptomic, proteomic, or metabolomic disease-specific datasets identified in this literature pass beyond the receptor electrophysiology studies; this is predominantly studied via targeted electrophysiology of recombinant mutant receptors plus mouse knock-in/knockout models, not unbiased omics.

Advanced technologies: Not identified — no single-cell, spatial transcriptomic, or CRISPR screen data specific to GABRB3-DEE43 found in this search.

7. Anatomical Structures Affected

Organ level: Primary and essentially exclusive organ involvement is the central nervous system (brain). No other organ systems are consistently affected, aside from the notable — and mechanistically informative — eye/ocular pigmentation phenotype (retinal/ocular hypopigmentation, mouse-model confirmed with a reported human correlate) reflecting a non-canonical role for GABRB3 outside strict CNS inhibitory signaling (PMID:28009282).

Body systems involved: Nervous system (primary); ophthalmologic (secondary, minor).

Tissue/cell level: Cerebral cortex (frontal-predominant EEG changes reported), hippocampus, thalamus, and cerebellum (vermal hypoplasia reported in Gabrb3-null mice and occasionally on human MRI). Cell populations: GABAergic inhibitory interneurons (CL:0000617) and their postsynaptic excitatory neuron targets, across multiple cortical/subcortical regions.

Subcellular level: Postsynaptic membrane / postsynaptic density (GABAergic synapse), where GABA_A receptor pentamers are trafficked, clustered (via gephyrin scaffolding), and gated. Suggested GO Cellular Component terms: GO:0032281 (AMPA... — not relevant), better: GO:0032279 (asymmetric synapse — not ideal), most precise: GO:0032590 (dendrite membrane) and GO:1902711 (GABA-A receptor complex) plus GO:0098982 (GABA-ergic synapse).

Localization/lateralization: Diffuse/bilateral cortical and subcortical involvement typical of a generalized channelopathy-type DEE (not focal/lateralized), though individual patients show focal-onset seizure semiology (e.g., frontal-predominant EEG changes) reflecting network-level, not structural-lesion, focality. UBERON terms: UBERON:0000955 (brain), UBERON:0001870 (frontal cortex), UBERON:0002037 (cerebellum), UBERON:0001954 (hippocampus).

8. Temporal Development

Onset: Congenital-to-infantile; the modal window is the first year of life, with reported medians ranging by cohort/variant class from 0.5 months (severe GOF, reduced-desensitization variants) to ~3.75–10.5 months. A subset of patients has normal early development before seizure onset; others present with neonatal hypotonia/feeding difficulty preceding seizures by weeks to months (PMID:26645412). Onset pattern is typically subacute-to-acute with rapid escalation to multiple seizure types ("cluster seizures" in 80.8% of one cohort).

Progression: Variable but frequently progressive/evolving — infantile spasms evolving into Lennox-Gastaut syndrome is a repeatedly documented trajectory (e.g., p.Asn120Asp, p.Glu180Gly, p.Tyr302Cys cases; PMID:26645412). Disease course is generally chronic and lifelong, with seizures typically pharmacoresistant ("refractory to treatment" per OMIM #617113) though a minority achieve seizure control (particularly in the LOF/febrile-onset subgroup).

Patterns: No spontaneous-remission pattern is emphasized in the literature; some patients achieve treatment-induced (partial) seizure reduction with polytherapy, ketogenic diet, or ACTH. A critical treatment-response window is implied by the variant-functional-class-guided pharmacology data: recognizing GOF vs. LOF status early may be clinically important for choosing (or avoiding) vigabatrin.

9. Inheritance and Population

Epidemiology: DEE43 itself is an ultra-rare, recently delineated (post-2015) molecular diagnosis without a population-level prevalence/incidence figure identified in the literature surveyed; it should be considered against the broader context that developmental and epileptic encephalopathies collectively have an estimated prevalence around 1 in 590 children. GABRB3 is recognized as "a new and emerging cause" of early infantile EE (title of PMID:26645412), consistent with a still-growing, under-ascertained case count (published cohorts to date: ~26–74 patients per major series).

Inheritance pattern: Autosomal dominant; virtually always de novo. Rare inherited (including parental mosaic) transmission is reported but not quantified precisely for GABRB3 specifically.

Penetrance: Reported as high/complete for the DEE43 phenotype among carriers of clearly pathogenic (functionally validated GOF/LOF) variants, though this is inferred from case-ascertainment cohorts (ascertainment bias likely inflates apparent penetrance) rather than population-based penetrance studies.

Expressivity: Markedly variable — even carriers of the identical variant can show discordant phenotypes (e.g., one of two patients with p.R232Q had bifrontal heterotopia on MRI, the other a normal MRI), and the GOF/LOF and structural-domain frameworks only partially explain this variability.

Genetic anticipation: Not applicable/not reported (this is not a repeat-expansion disorder).

Germline/parental mosaicism: Plausible and clinically important for genetic counseling — apparently unaffected parents of a de novo GABRB3 proband cannot be assumed to have zero recurrence risk without deep/targeted sequencing to exclude low-level mosaicism; general DEE-cohort mosaicism detection rates (not GABRB3-specific) are on the order of ~10–12%.

Founder effects: None reported.

Consanguinity: Not relevant — this is a dominant, not recessive, disorder.

Carrier frequency: Not applicable (dominant, de novo disorder; no meaningful "carrier" state as in recessive disease).

Population demographics: No specific ethnic, geographic, or sex-ratio skew is reported for GABRB3-DEE43 in the sources reviewed; published cohorts are multinational (European, North American, Chinese) with no stated enrichment. Age distribution of affected/reported individuals spans infancy through young adulthood in follow-up cohorts (e.g., 11–20-year-old follow-up range in the Epi4K Consortium 2016 report referenced in secondary sources).

10. Diagnostics

Clinical/laboratory tests: No specific diagnostic biomarker (blood/urine/enzymatic) exists for GABRB3-DEE43; diagnosis is clinical (seizure phenotype + developmental encephalopathy) confirmed by molecular genetic testing.

EEG (electrophysiology): Central to diagnostic workup. Findings include focal, multifocal, or generalized sharp waves associated with seizures, sometimes with hypsarrhythmia (in infantile-spasms presentations), and in at least one detailed case, "generalized fast activity, more prominent over the frontal regions" with interictal multifocal discharges (PMID:26645412).

Neuroimaging: Brain MRI is frequently normal but should be obtained; when abnormal, findings include polymicrogyria, diffuse hypomyelination, cerebellar hypoplasia, cortical/brainstem atrophy, or (rarely) bifrontal heterotopia — none of these is diagnostic in isolation, and structural abnormality does not reliably predict severity given documented discordance between MRI findings in carriers of an identical variant.

Genetic testing (the definitive diagnostic modality): - Epilepsy gene panels including GABRB3 (and the broader GABA_A receptor subunit gene family — GABRA1, GABRB1-3, GABRG2) are the recommended first-tier test for infantile-onset DEE of unclear etiology - Whole exome sequencing (WES) or whole genome sequencing (WGS) with trio (proband + both parents) analysis is standard for confirming de novo status and is the most efficient approach when the clinical presentation is not narrowly suggestive of a single-gene panel target - Chromosomal microarray (CMA) should be considered/performed to exclude the alternative, mechanistically distinct 15q11.2-q13.1 contiguous-gene deletion (Angelman syndrome) that also removes GABRB3, since clinical overlap (developmental delay, seizures, hypotonia) exists and management/counseling implications differ substantially - Variant interpretation: ACMG/AMP criteria via ClinVar/ClinGen; the strongest evidence for pathogenicity in this gene is (a) de novo occurrence and (b) functional electrophysiological validation (GOF/LOF classification) — increasingly incorporated into clinical variant curation given its treatment relevance - Population frequency filtering: gnomAD absence/rarity of the variant supports pathogenicity, as expected for a dominant de novo disease gene

Differential diagnosis: Other genetic DEEs presenting in infancy with multifocal/refractory seizures and developmental delay — SCN1A (Dravet syndrome; notably, at least one GABRB3 variant has been reported presenting with a Dravet-like phenotype, PMID for Pavone et al. 2020 case report), STXBP1, KCNQ2, CDKL5, other GABA_A subunit genes (GABRA1, GABRB1, GABRB2, GABRG2), and — critically — 15q11.2-q13.1 deletion (Angelman syndrome), which must be excluded by CMA given phenotypic overlap and shared GABRB3 involvement via a different mechanism.

Screening: No newborn screening or population carrier-screening applicability (rare dominant de novo disorder); prenatal testing (via known familial variant, in the rare setting of parental mosaicism/inherited transmission) and preimplantation genetic testing are theoretically available once a familial pathogenic variant is established.

11. Outcome/Prognosis

Survival/mortality: Generally guarded in the severe end of the spectrum — the most severe gain-of-function subgroup (reduced receptor desensitization, EIMFS-like presentation, movement disorder) carries a documented risk of early mortality (PMID:37647766). Precise survival statistics (5-year, 10-year) are not established in a population-based way given the rarity and recency of molecular delineation of this disorder.

Morbidity/function: Substantial — global developmental delay (~96% of one cohort), intellectual disability ranging mild to profound, non-verbal status and severe motor disability reported in the most severely affected patients (e.g., some non-verbal with severe motor disability by age 1 year in the pore-domain-variant cases). No validated disease-specific QOL instrument data identified.

Disease course/complications: Chronic, often lifelong pharmacoresistant epilepsy; evolution to Lennox-Gastaut syndrome is a recognized complication trajectory. Secondary complications typical of severe childhood DEE (aspiration risk, injury from seizures/falls, feeding difficulties) can be inferred but are not GABRB3-specific in the literature surveyed.

Recovery potential: Variable; a minority of patients (particularly in the LOF/febrile-seizure-onset subgroup) achieve better seizure control, and isolated case reports describe good response to specific agents (e.g., clonazepam in one early-onset case, PMID:29390378).

Prognostic factors: - Functional variant class (GOF vs. LOF) is the single strongest identified prognostic axis — GOF associates with younger onset, more severe ID, and lower likelihood of seizure freedom - Desensitization kinetics within the GOF class further stratifies severity (reduced desensitization = most severe, including movement disorder and early-mortality risk; PMID:37647766) - Structural domain of the variant (extracellular vs. pore-lining transmembrane vs. coupling junction) correlates with epilepsy type (generalized vs. focal) and ID severity (PMID:34906499) - No validated molecular prognostic biomarker beyond the variant's own functional/structural classification exists.

12. Treatment

General approach: No disease-modifying or gene-targeted therapy currently exists (as of this research pass, no GABRB3-specific gene therapy or ASO program was identified in clinical trials — searches for GABRB3-directed antisense oligonucleotide or gene therapy trials returned only tangentially related programs, e.g., the Angelman syndrome apazunersen ASO trial, which targets a different gene, UBE3A). Management is symptomatic, anti-seizure-drug-based, and multidisciplinary. Treatment is typically polytherapy with antiepileptic drugs (AEDs), often escalated to ACTH, ketogenic diet, or vagal nerve stimulation (VNS) in refractory cases; overall prognosis for seizure control is poor, requiring multiple AEDs or combination approaches for even partial control.

A genuinely precision-medicine-relevant finding — variant-guided pharmacology: - Vigabatrin hypersensitivity is a specific, mechanistically explained adverse phenomenon: gain-of-function GABRB3 variants (e.g., p.Glu77Lys, p.Thr287Ile) produce severe drowsiness, hypotonia exacerbation, and respiratory difficulty on vigabatrin (which enhances tonic GABAergic current by blocking GABA-transaminase, raising extracellular GABA) — occurring in an estimated ~5% of GABRB3 DEE patients, reversible on discontinuation. Conversely, a loss-of-function truncating variant (p.Arg194) showed a favorable vigabatrin response, consistent with the variant compensating for reduced tonic inhibitory drive (PMID:33585817). - Benzodiazepines (e.g., nitrazepam, clonazepam) did not exacerbate symptoms in GOF-variant patients, despite also being GABAergic-potentiating agents, because they selectively enhance phasic (synaptic) rather than tonic (extrasynaptic) GABA_A currents — offering a mechanistically rational, safer alternative to vigabatrin in this population. One GOF patient (β3-E77K) achieved significant seizure reduction over 6 months on nitrazepam plus ketogenic diet without adverse response (PMID:33585817). A separate case report documents effective clonazepam treatment of early-onset GABRB3-associated EE (PMID:29390378). - Cannabidiol ameliorated atypical absence seizures in the Gabrb3+/D120N Lennox-Gastaut mouse model, alongside conventional AEDs (mouse-model evidence; PMC7238755, and a 2026 Epilepsia Open follow-up study, DOI:10.1002/epi4.70289) — translational relevance to human CBD (Epidiolex) use in GABRB3-associated LGS is plausible but not yet clinically validated in the human literature surveyed here. - Ketogenic diet is used as an adjunct in refractory GABRB3-DEE and is broadly supported by ketogenic-diet-efficacy-by-genetic-etiology literature (PMC6054992, not GABRB3-specific), and specifically reported effective (combined with nitrazepam) in at least one GOF patient (PMID:33585817). - ACTH is used for infantile-spasms presentations as in DEE generally (OMIM #617113 clinical summary), though no GABRB3-specific outcome data for ACTH monotherapy was identified. - Vagal nerve stimulation (VNS)* is used as an adjunct in drug-resistant cases per general DEE43 clinical management summaries.

Suggested NCIT terms: NCIT:C15632 (Chemotherapy — not applicable; use NCIT:C15986 Pharmacotherapy for AEDs generically), NCIT:C15986 (Pharmacotherapy) with therapeutic_agent bound to CHEBI terms for vigabatrin (CHEBI:9953), clonazepam (CHEBI:3756), nitrazepam (CHEBI:7594), cannabidiol (CHEBI:69478); NCIT:C15447 (Dietary Intervention) for ketogenic diet; device-category term for VNS (no clean NCIT clinical-action term per dismech guidance — omit therapeutic_modality: DEVICE inference from ID alone, verify manually).

Experimental/pipeline: No GABRB3-specific investigational drug, ASO, or gene-therapy program was identified as being in active clinical trials as of this research (August 2026); the field's precision-medicine advances to date are pharmacogenomic (matching existing GABAergic drugs, especially vigabatrin avoidance/benzodiazepine preference, to a patient's functionally characterized GOF/LOF variant) rather than gene-specific novel therapeutics.

Treatment outcomes/adverse events: Vigabatrin-associated adverse events in GOF-variant carriers (severe drowsiness, hypotonia, respiratory compromise) are the best-characterized genotype-specific adverse-event signal in this disease (PMID:33585817); this is a rare but clinically important example of a "reverse-precision-medicine" hazard — a normally beneficial, first-line infantile-spasms drug becoming actively harmful in a molecularly defined subgroup.

13. Prevention

Primary prevention: Not applicable in the traditional sense — as a de novo dominant genetic disorder, there is no modifiable environmental/behavioral primary prevention strategy. The only "prevention" lever is genetic: prenatal or preimplantation genetic testing in families with a known familial variant (relevant primarily in the rare inherited or parental-mosaicism scenario).

Secondary prevention/early detection: Early recognition of the seizure phenotype and prompt genetic diagnosis (ideally via trio WES/WGS or an epilepsy gene panel) is clinically valuable because it can (a) guide avoidance of vigabatrin in patients found to carry gain-of-function variants, thereby preventing an iatrogenic adverse drug reaction, and (b) prompt CMA to exclude the alternative, differently-managed 15q11.2-q13.1 deletion (Angelman syndrome) diagnosis.

Genetic counseling: Recommended for all families given the de novo dominant mechanism; recurrence risk counseling should account for possible (typically low, but non-zero) parental gonadal/somatic mosaicism, generally quoted in the broader de novo epilepsy literature as an empiric ~1–5% general recurrence risk absent confirmed parental mosaicism, rising toward ~50% if mosaicism in a parent's germline is specifically demonstrated.

Public health/prophylaxis: Not applicable — this is not a preventable-exposure or vaccine-preventable disease.

14. Other Species / Natural Disease

Taxonomy/model relevance: No naturally occurring GABRB3-associated disease has been documented in companion animals or wildlife (no OMIA entry identified in this pass); essentially all cross-species data derive from engineered laboratory mouse models rather than natural veterinary disease.

Orthologous gene: Mouse Gabrb3 (MGI:95621), located on mouse chromosome 7 in the syntenic Angelman/Prader-Willi region; highly conserved with human GABRB3.

Comparative biology: The mouse ortholog has been essential for establishing causality and mechanism (see Model Organisms, below); no comparative pathology data across other vertebrate species beyond mouse was identified.

Transmission: Not applicable (non-infectious, non-zoonotic genetic disorder).

15. Model Organisms

Gabrb3-null (knockout) mice — the foundational model (PMID:9763493; PMID:9108119): - Complete or partial loss of the β3 subunit in mice recapitulates electroencephalographic abnormalities, spontaneous seizures, and a constellation of behavioral characteristics overlapping with human Angelman syndrome (motor deficits, impaired learning/memory, hyperactivity, abnormal social/exploratory behavior, non-selective attention deficits) and with autism-spectrum-relevant phenotypes (DeLorey et al., J Neurosci 1998, PMID:9763493; earlier report of cleft palate + epilepsy + hypersensitive behavior in Gabrb3-null mice, PMID:9108119). - Seizures in these mice show a pharmacological response profile to antiepileptic drugs paralleling human Angelman syndrome patients, supporting translational/construct validity for at least the GABRB3-deficiency (LOF) arm of the human spectrum. - An additional, non-neurological phenotype — near-complete loss of retinal pigmentation due to atrophied melanosomes — was identified in Gabrb3-null mice, paralleling the human ocular hypopigmentation phenotype and revealing an unexpected pigmentation-relevant GABRB3 function (PMID:28009282). - Ube3a-to-Gabrb3 large maternal deletion mice (modeling the human Class I/II Angelman deletion rather than isolated Gabrb3 loss) show additional impaired ultrasonic vocalization, increased spontaneous seizure activity, and broader motor/learning/anxiety phenotypes relative to Ube3a-only models, directly demonstrating the contiguous-gene severity-modifying role of Gabrb3 co-deletion (PMC2924885 / PLOS ONE).

Point-mutation knock-in mice (modeling specific human DEE43/LGS variants directly): - Gabrb3+/D120N knock-in mice (modeling the human de novo p.D120N Lennox-Gastaut variant): frequent spontaneous atypical absence seizures, plus less-frequent tonic, myoclonic, atonic, and generalized tonic-clonic seizures; behaviorally, impaired learning/memory, hyperactivity, impaired social interaction, and increased anxiety — closely recapitulating the human LGS behavioral phenotype (Brain Communications 2020; PMC7238755). - Gabrb3+/N328D knock-in mice (modeling the human p.N328D LGS variant): spontaneous seizures and cognitive impairment including spatial learning/memory deficits and locomotor abnormality (IJMS 2023; PMC10179596). - Cannabidiol treatment reduced atypical absence seizures and epileptic spasms in the Gabrb3+/D120N model, supporting a translational rationale for CBD trial consideration in human LGS-phenotype GABRB3 patients (Epilepsia Open, DOI:10.1002/epi4.70289).

Model characteristics — recapitulation and limitations: - Strengths: Both the knockout and the disease-variant knock-in models strongly recapitulate core human features — spontaneous seizures of multiple types, EEG abnormality, cognitive/behavioral impairment, and (for D120N/N328D) an LGS-like behavioral and seizure profile closely matching the specific human genotype being modeled. - Limitations: Knockout (complete loss) mice most directly model the LOF end of the human spectrum and the Angelman-syndrome-adjacent phenotype, not the full human GOF spectrum; point-mutation knock-in models (D120N, N328D) are LGS-specific and each represents only one of the 44+ characterized human variants, so extrapolation of drug-response findings (e.g., CBD efficacy) to other GABRB3 variants — especially across the GOF/LOF divide — should be treated as a HUMAN_MODEL_MISMATCH-flagged inference rather than assumed generalizable.

Model resources: MGI:95621 (Gabrb3); knockout and knock-in alleles referenced in the cited primary literature are generated in academic laboratories (Olsen/DeLorey group for the original knockout; Macdonald/Vanderbilt-affiliated group for D120N/N328D knock-ins) rather than centrally cataloged in IMSR/EMMA/MMRRC as far as identified in this search — verify specific allele/strain repository availability directly with MGI before citing a model resource in curation.

Summary Table of Key Primary Citations (PMID-anchored)

Topic	PMID	Citation summary
Original GABRB3 EE description	26645412	Papandreou et al. 2016, Dev Med Child Neurol — first GABRB3 early infantile EE cohort
GOF/LOF genotype-phenotype split	35383156	Absalom, Liao, Johannesen et al. 2022, Nat Commun — 74 patients, 44 variants
Structural mapping / domain correlation	34906499	2021, Genetics in Medicine — 71 individuals, 3D structural mapping
Chinese multicenter cohort	34698933	Yang et al. 2022, J Neurol — 26 patients, novel variants
Vigabatrin hypersensitivity mechanism	33585817	Absalom et al. 2020, Brain Commun
Desensitization/severity correlation	37647766	2024, Brain — 20 GOF variants, desensitization kinetics vs. severity
Synaptic clustering mechanism	31435640	2019 — trafficking/clustering differences across variants
D120N knock-in mouse (LGS model)	— (PMC7238755)	Brain Commun 2020
N328D knock-in mouse (LGS model)	— (PMC10179596)	IJMS 2023
Gabrb3-null mouse — original AS/epilepsy model	9763493	DeLorey et al. 1998, J Neurosci
Gabrb3-null mouse — cleft palate/epilepsy	9108119	Homanics et al. 1997
Ocular hypopigmentation phenotype	28009282	Beyond epilepsy and autism
Childhood absence epilepsy association	10509183	Feucht et al. 1999
Autism rare-variant significance	25363760	De Rubeis et al. 2014 (SFARI ~95% confidence gene)
Clonazepam-responsive case report	29390378	Early-onset GABRB3 EE case

Caveats for curation: Several figures above (e.g., cohort percentages) come from small (n=26–74) case series and should be flagged as such rather than treated as population-level prevalence statistics. MONDO/Orphanet CURIEs for DEE43 specifically were not independently confirmed via OAK in this research pass and must be verified before use in the KB entry. The MRI-discordance-in-identical-genotype finding and the CBD/mouse-model translational claim are both good candidates for HUMAN_MODEL_MISMATCH/variability discussion nodes rather than settled causal claims.

Ask OpenScientist

OpenScientist Report

Classifications

Mappings

Inheritance

Mechanistic Hypotheses

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Diagnosis

Prevalence

Differential Diagnoses

Animal Models

Source YAML

References & Deep Research

References

Deep Research

GABRB3-Related Developmental and Epileptic Encephalopathy: Comprehensive Research Report

1. Disease Information

2. Etiology

3. Phenotypes

Core seizure phenotypes (symptoms/signs, HPO-mappable)

Developmental/cognitive phenotypes

Movement disorder phenotypes (severe end of spectrum)

Ophthalmologic phenotype

Neuroimaging (structural) phenotypes

Characteristics

4. Genetic/Molecular Information

5. Environmental Information

6. Mechanism / Pathophysiology

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome/Prognosis

12. Treatment

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Summary Table of Key Primary Citations (PMID-anchored)